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ABSTRACT 
Objectives: The Saskatchewan Medication Assessment Program (SMAP) is a community 
pharmacy based medication assessment program introduced in 2013, which has not been 
formally evaluated. The objectives of this research were to (1) determine the extent to which 
pharmacists believe they are fulfilling the purposes of the SMAP; (2) describe pharmacists’ 
perceptions of the barriers and facilitators to fulfilling the purposes of the SMAP; and (3) 
determine strategies pharmacists would like to see implemented to assist them to provide the 
SMAP. 
Methods: Mixed methods study in which a web-based questionnaire was distributed by the 
Pharmacy Association of Saskatchewan. Pharmacists were eligible to participate if they practiced 
in a community pharmacy setting. The questionnaire consisted of a combination of 53 Likert-
scale and free-text questions.  
Results: The survey had 228 respondents (response rate = 20.3%, n=228/1124). The majority of 
respondents were staff pharmacists (64.3%, n=128/199) who worked 31-40 hours per week 
(57.5%, n=115/200), and completed between one and five SMAP assessments in a typical month 
(79.2%, n=164/207). Most respondents were in agreement that the SMAP was meeting its 
intended purposes. For instance, 89.7% (n=192/214) of respondents agreed or strongly agreed 
that SMAP assessments improved medication safety for seniors. Pharmacists also agreed that 
they were confident in identifying drug related problems (88.2%, n=172/195) and that they were 
comfortable making recommendations to physicians (81.7%, n=156/191). However, respondents 
also revealed that they sometimes have trouble identifying drug related problems because they 
do not have enough of the patients medical history (67.2%, n=131/195) and that they do not 
regularly contact the physician to request additional patient information (89.7%, n=175/195). 
Respondents reported that a lack of time, patients not meeting eligibility criteria, and patients 
having difficulty coming into the pharmacy as common barriers for providing SMAP 
assessments. Respondents also reported that good teamwork, employer support, and a belief that 
SMAP assessments improve patient care helped them to provide SMAP assessments.  
Conclusions: Pharmacists in Saskatchewan perceive that the SMAP is fulfilling it’s intended 
purposes, however the findings revealed that community pharmacists experience several barriers 
to providing SMAP assessments that they wish to be addressed to improve the provision and 
quality of the program.  
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CHAPTER 1 
INTRODUCTION 
Within the last decade there has been a push for pharmacists to take on more clinical 
roles to improve patients’ health and quality of life. 1,2 As their knowledge and skills are 
recognized, pharmacists are being better utilized and their scope of practice is expanding. 1 An 
emerging trend in pharmacy is the expansion of pharmacists’ clinical roles through government-
funded programs that pay for pharmacists’ services such as minor ailment management, 
enhanced prescriptive authority, administering drugs by injection, and medication assessments. 1 
Community pharmacists are in a particularly good position to provide these new clinical 
services, as they are highly accessible to the public. 1   
 One new professional service that has become particularly common in community 
pharmacies across Canada is the medication assessment. 3 The goals of this service are to update 
patient’s medication lists and also to ensure that patients are receiving optimal drug therapy by 
identifying and resolving drug therapy problems (DTPs). Most provinces have slightly different 
versions of community pharmacy-based, pharmacist-led medication assessment programs for 
patients who meet program-specific eligibility criteria. 3 Many provincial governments fund the 
medication assessment programs and pharmacies are paid for providing these services. 3 The 
Saskatchewan Medication Assessment Program (SMAP) was introduced on July 8th, 2013. 4,5 
 There is limited evidence that these types of medication assessment programs improve 
patient health outcomes, such as reducing hospitalizations and mortality. 6-12 However, there are 
several studies that suggest these programs may be helpful to identify and resolve DTPs and 
improve prescribing quality, quality of life scores, medication appropriateness index (MAI) 
scores, medication adherence, patient knowledge, laboratory values, pharmacists’ professional 
fulfillment, patient loyalty to a pharmacy, and satisfaction scores for both clinicians and patients. 
6-8,13-15 Unfortunately, these studies are extremely heterogeneous with respect to the types of 
medication assessment programs that were evaluated (i.e., programs can differ significantly in 
depth of inquiry, patient support, and the quality of recommendations provided), the endpoints 
that were measured, and the research methodologies that were used. 6-16 Consequently, it is 
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impossible to reliably translate the evidence from these studies to other medication assessment 
programs, such as the SMAP in Saskatchewan.  
The SMAP is a relatively new medication assessment program that has not yet been 
formally evaluated. The purpose of this study was to take a first step in evaluating the SMAP by 
exploring pharmacists’ experiences with, and perceptions of, the SMAP. The goal is to determine 
the extent to which pharmacists believe they are fulfilling the purposes of the SMAP outlined by 
the Saskatchewan Ministry of Health 4,5, identify the barriers and facilitators to fulfilling the 
purposes of the SMAP, and determine strategies pharmacists would like to see implemented to 
help them to fulfill the purposes of the SMAP.  
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
2.1 Changing Pharmacy Practice 
 The focus of community pharmacy practice, and pharmacy practice in general, has 
shifted several times in history. 17 Holland and Nimmo summarized the history as:  
 
The story tells of frequent, dramatic changes in practice spurred by advances in 
technology, by economic alterations, and by legislation. Between 1860 and the late 
1990s, the profession’s preferred orientation has moved from manufacturing, to 
compounding, to distribution, to a more clinical role, and finally to pharmaceutical care. 
Seen in retrospect, these shifts seem so large as to represent a series of entirely different 
professions bound only by a common name and an association with a common product, 
medications. 17 
 
In 1990 an article was published by Hepler and Strand that made the case for the need for 
pharmacy practice to adapt. 18 The authors suggested that pharmacists focused too much on 
tangible drug products, rather than providing direct patient care and taking responsibility for 
individual patient’s drug therapy outcomes. 18 Recognizing the emerging issue of preventable 
drug-related morbidity and mortality facing healthcare, they introduced and defined the concept 
of patient-centred pharmaceutical care. 18 Hepler and Strand defined pharmaceutical care as, “… 
the responsible provision of drug therapy for the purpose of achieving definite outcomes that 
improve a patient’s quality of life”. 18 They also stated that pharmaceutical care: 
“… involves the process through which a pharmacist cooperates with a patient and other 
professionals in designing, implementing, and monitoring a therapeutic plan that will 
produce specific therapeutic outcomes for the patient”. 18 
Hepler and Strand suggested that it was time for pharmacists to make a greater contribution to 
the healthcare system and secure their professional role. 18 They believed that this could be 
achieved by the provision of pharmaceutical care services that were individualized and focused 
on the patient’s wellbeing. 18 
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In January 2007 the Blueprint Task Force was established in Canada. 2 The goal of the 
Task Force was to outline a vision for pharmacy to align the efforts of Canadian pharmacists and 
pharmacy organizations with the healthcare needs of Canadians. 2 The overarching message of 
the Vision for Pharmacy was the desire for, “Optimal drug therapy outcomes for Canadians 
through patient-centred care”. 2 The task force recognized that the healthcare needs of Canadians 
were changing and as such there was increased pressure on the healthcare system. 2 It was argued 
that pharmacists were in a unique position to help improve this situation given their expertise in 
drug therapy. 2 Ultimately it was agreed that the practice of pharmacy must shift its focus from 
being product-centred to patient-centred in order to contribute optimally to the Canadian 
healthcare system. 2 
 
2.2 Common Clinical Services Offered in Community Pharmacy 
 Since the development of the Blueprint for Pharmacy in 2008, several programs have 
been created across Canada in an effort to move towards the Blueprint’s goals. 2 These programs 
include: minor ailment management, smoking cessation counselling, enhanced prescriptive 
authority, administering drugs by injection, and medication assessments. 19 
 
2.2.1 Minor Ailment Management 
 Pharmacists in Alberta, Saskatchewan, Manitoba, Quebec, New Brunswick, Nova Scotia, 
Prince Edward Island, and Newfoundland and Labrador can assess and prescribe for a growing 
list of minor ailments. 19 This is a relatively new and expanded scope of practice that permits 
community pharmacists to assess that a patient has made a correct self-diagnosis of a minor 
ailment and provide the patient with a prescription for a medication that they would otherwise be 
unable to access without an appointment with a physician or a nurse practitioner. 20  
In Saskatchewan, pharmacists have been able to prescribe for minor ailments since 
February 1st, 2012. 21 The original list of conditions that pharmacists in Saskatchewan could 
prescribe for included: acne, cold sores, and insect bites. 21 The service has since been expanded 
to include: allergic rhinitis, atopic dermatitis, diaper dermatitis, dysmenorrhea, gastroesophageal 
reflux disease (GERD), headache, hemorrhoids, musculoskeletal strains and sprains, oral 
aphthous ulcers, oral thrush, impetigo, folliculitis, tinea corporis infection, tinea cruris skin 
infection, and tinea pedis infection. 20 The advantage of minor ailment prescribing by pharmacists 
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is that it allows patients access to effective medications to treat relatively minor, self-limiting 
conditions that often do not require a physician assessment. 20   
 
2.2.2 Smoking Cessation Counselling 
 Most provinces fund smoking cessation programs that are provided to patients by a 
variety of healthcare practitioners, including pharmacists. The Canadian Pharmacists Association 
(CPhA) offers a continuing education program called the QUIT (Quit Using and Inhaling 
Tobacco) Smoking Cessation Program that is designed to enhance pharmacists’ abilities to 
provide smoking cessation services. 22 In Saskatchewan, the PACT (Partnership to Assist with 
Cessation of Tobacco) program was developed in 2004. 23 Initially PACT was designed to 
support community pharmacists in encouraging their patients to stop using tobacco products and 
later the program was expanded to all healthcare professionals in Saskatchewan. 23 Community 
pharmacists who become PACT certified are paid a fee by the provincial drug plan to provide 
their patients with smoking cessation counseling. 24 The Tobacco Addiction Recovery (TAR) 
program is also available in Saskatchewan and is similar to PACT, but TAR was developed 
specifically for smoking cessation in Aboriginal communities and the promotion of only scared 
tobacco use. 23 
 
2.2.3 Enhanced Prescriptive Authority 
 Most Canadian provinces and territories have expanded pharmacists’ traditional scope of 
practice and have granted pharmacists enhanced prescriptive authority. 19 There are variances 
between each province, but the most common prescribing practices that can be undertaken by 
pharmacists include: providing emergency prescription refills, renewing or extending existing 
prescriptions, changing a drug dosage or formulation, and therapeutic substitution. 19 Enhanced 
prescriptive authority activities enable pharmacists to reduce disruptions to drug therapy and 
avoid unnecessary physician or emergency room visits.  Saskatchewan pharmacists have been 
providing enhanced prescriptive authority to their patients since March 4, 2011. 25  
 
2.2.4 Administering Drugs by Injection 
Pharmacists in British Columbia, Alberta, Manitoba, Ontario, New Brunswick, Nova 
Scotia, Prince Edward Island, Newfoundland and Labrador, and Saskatchewan can administer 
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drugs by injection. 19 In Saskatchewan, pharmacists began providing influenza vaccinations in 
October 2015 and pharmacies are paid a fee of $13.00 by the Drug Plan and Extended Benefits 
Branch. 26 Saskatchewan pharmacists are able provide other intramuscular and subcutaneous 
injections, however the fee to provide the service must be paid by the patient. 26  
By having pharmacists offer injections in community pharmacies, patients have the 
option to receive immunizations such as the influenza vaccine at a time and in a location that is 
convenient for them.  The service also avoids the hassle of having patients get a prescription for 
an injectable drug from a physician, having it dispensed at a pharmacy, and then making another 
appointment to have the drug administered by the physician.  Administration of injectable drugs 
by pharmacists has been shown to increase vaccination rates and has the potential to improve 
adherence to injectable drug therapy and free up physician time. 27  
 
2.2.5 Medication Assessments 
 A medication assessment, also referred to as a medication review, has been defined as: “a 
structured critical examination of a patient’s medications with the objectives of reaching an 
agreement with the patient about their treatment and optimizing the impact of medications on the 
patient’s health outcomes”. 7 More specifically a medication assessment is a clinical service in 
which a pharmacist interacts with a patient or caregiver to collect a detailed medication history, 
and uses that information (along with additional patient history collected from other sources) to 
ensure that the patient’s medications are all indicated, safe, and effective.  In addition, the 
pharmacist ensures that patients understand why they are taking their medications, how to take 
them, and encourages them to be adherent.  
In Canada, eight provinces have provincially funded medication assessment programs: 
British Columbia, Alberta, Saskatchewan, Ontario, New Brunswick, Nova Scotia, Prince Edward 
Island, and Newfoundland and Labrador. 3 This is not a particularly new service for pharmacists 
to provide, but having it offered in a community pharmacy (and funded by provincial Ministries 
of Health) is a relatively new practice. Ontario’s MedsCheck program, introduced in 2007, was 
the first government funded medication assessment program in Canada. 28  
The Pharmacy Association of Saskatchewan (PAS) developed a program for compliance 
packaging and medication assessments for homecare and mental health patients that was 
implemented in 2010. 29,30 Under this program, community pharmacies are reimbursed by the 
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provincial drug plan for completing a yearly medication assessment, along with monthly 
compliance packaging. 29,30 A second medication assessment program, the Saskatchewan 
Medication Assessment Program (SMAP), was introduced in July 2013. 4,5 Under SMAP, 
community pharmacies are remunerated for pharmacists’ completing medication assessments 
with Saskatchewan residents over the age of 65 who also meet additional eligibility criteria (e.g., 
taking five or more chronic medications, or taking an anticoagulant listed in section 20:12.04 of 
the Saskatchewan Formulary, or taking a medication listed in the most current American 
Geriatrics Society (AGS) Beers Criteria for Potentially Inappropriate Use in Older Adults). 4,5 
 
2.3 What Happens During a Medication Assessment?  
 Healthcare providers other than pharmacists can perform medication assessments, 
however, pharmacists are generally considered to be the most qualified professional to offer this 
service due to their specialized drug therapy knowledge and training.  Medication assessments 
are offered in a variety of settings, ranging from hospitals, physician clinics, primary health 
centres, and, most recently, in community pharmacies.  
The depth of inquiry and the subsequent quality of recommendations and patient support 
provided during the medication assessment has been known to vary significantly amongst 
medication assessment programs.  Hatah et al recognized three discreet types of medication 
assessments that are typically offered by pharmacists, which they categorized as: prescription 
reviews, adherence support reviews, and clinical reviews. 7  
At one end of the spectrum (i.e., the “prescription reviews”), the service provided is quite 
superficial and technical in nature.  These prescription reviews focus on confirming that no 
discrepancies exist between the patient’s medication list on file in the pharmacy or clinic and the 
medications the patient is actually taking. 7 This type of service is also commonly referred to as 
medication reconciliation, particularly when it is provided in an institutional or hospital setting.   
“Adherence support reviews” are a slightly more advanced assessment that, in addition to 
the steps performed in the “prescription review”, the pharmacist also ensures that the patient 
knows what each medication is for, how to take each medication properly, and that there are no 
obvious adverse effects, contraindications or drug interactions. 7 The MedsCheck program in 
Ontario is an example of an adherence support review. 31  
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At the other end of the spectrum is the “clinical review”, which is the most in-depth and 
comprehensive type of medication assessment.  It entails a thorough patient interview and 
examination of relevant patient medical records and laboratory results, with the goal of collecting 
a detailed and comprehensive patient history related to medication use and chronic disease 
management. 7 As with “prescription reviews” and “adherence support reviews”, “clinical 
reviews” aim to: (1) confirm that no discrepancies exist between the patient’s medication list on 
file in the pharmacy or clinic and the medications the patient is actually taking; and (2) ensure 
that the patient knows what each medication is for, how to take each medication properly, and 
that there are no obvious adverse effects, contraindications or drug interactions. 7 However, these 
clinical reviews also aim to ensure that the overall medication regimen is appropriate, effective 
and safe, by identifying and resolving any drug therapy problems. 7 There are eight recognized 
types of drug therapy problems that might be identified when performing a clinical review: (1) 
unnecessary drug therapy, (2) wrong drug, (3) dose is too low, (4) dose is too high, (5) adverse 
drug reaction, (6) non-adherence, (7) additional drug therapy needed, and (8) interaction with 
another drug, a disease, a food, or a lab test. 4 
The medication assessment services offered in community pharmacies in Canada vary 
significantly from province to province, and can fall anywhere on this spectrum, ranging from 
prescription reviews to clinical reviews. 3 Alberta and British Columbia have both developed two 
medication assessment services that differ on the level of assessment offered. 32,33 In Alberta there 
is a Comprehensive Annual Care Plan offered to patients with “complex needs” that would fit 
the description of a clinical review and a Standard Medication Management Assessment that 
would be considered an adherence support review. 32 Pharmacists in British Columbia initially 
offer a Medication Review – Standard (MR-S), similar to an adherence support review, and if a 
medication management issue is identified a Medication Review – Pharmacist Consultation 
(MR-PC), similar to a clinical review, is offered to the patient. 33 
 Several factors can come into play when determining which patients will receive a 
medication assessment in a community pharmacy, including: whether or not the patient meets the 
eligibility criteria for the medication assessment program offered in the jurisdiction; the 
willingness of the patient to participate; the pharmacists’ judgment of the potential benefit of the 
service to the individual patient; and the availability of the pharmacist and patient at a mutually 
acceptable time. In Ontario a study was done to determine what factors affect whether an eligible 
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patient receives a community pharmacists-led medication review under the annual MedsCheck 
service. 31 All Ontario residents taking three or more prescription medications for chronic 
conditions are eligible for a medication assessment under the MedsCheck program. 31 The study 
population was limited to residents over 65 years of age because the drug claim data in Ontario 
was only available for seniors. 31 Utilizing data from April 2012 to March 2013, a statistical 
model was used to determine which factors affected whether or not an eligible senior received a 
MedsCheck assessment. 31 It was found that factors increasing the likelihood of receiving a 
MedsCheck included: having a prior MedsCheck service (OR = 3.03; 95% CI, 2.98-3.09); 
having a new prescription claim on the eligible claim date for a MedsCheck assessment (OR = 
1.78; 95% CI, 1.74-1.81); high risk medication use (OR = 1.09; 95% CI, 1.07-1.12); and a 
diagnosis of hypertension (OR = 1.18; 95% CI, 1.15-1.21). 31 Factors decreasing the likelihood of 
receiving a MedsCheck assessment included: a diagnosis of dementia (OR = 0.57; 95% CI, 0.55-
0.60), depression (OR = 0.90; 95% CI, 0.86-0.95), or heart failure (OR = 0.88; 95% CI, 0.86-
0.91); older age (OR = 0.72; 95% CI, 0.69-0.74 for 86+ years vs. 66-70 years); female sex (OR = 
0.90; 95% CI, 0.89-0.92); patients receiving potentially inappropriate medications (OR = 0.90; 
95% CI, 0.88-0.91) or a large number of medications (OR = 0.44; 95% CI, 0.43-0.46 for 11+ 
medications vs. 0-4 medications); patients using a pharmacy that had a high volume of claims 
(OR = 0.65; 95% CI, 0.63-0.67 for highest vs. lowest volume); and patients living in a rural 
community (OR = 0.74; 95% CI, 0.71-0.77 for rural vs. major urban). 31 The research showed 
that MedsCheck assessments might not, in all cases, be reaching the patients that need them 
most. 31 It was suggested that eligibility criteria could be adjusted to better align with patient need 
and that, “policies regarding current and future medication review programs may need to evolve 
to ensure that those at greatest need receive timely and comprehensive medication reviews”. 31 
 
2.4 How common are Medication Assessment Programs in Canada? 
 Eight provinces in Canada have government-funded, pharmacist-led medication 
assessment programs that are offered by community pharmacists. 3 The first of these programs 
was Ontario’s MedsCheck program that was introduced in April 2007, which is intended to 
include a face-to-face meeting with the patient and their community pharmacist that takes 
approximately 20-30 minutes. 34 During the first 6 years (2007 – 2013) of the program a total of 
1,498,440 Ontario residents received a MedsCheck Annual (MCA). 35 In the first month of the 
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program 1494 of the 3132 pharmacies in Ontario had provided at least one MCA. 35 The number 
of MCA claims and number of participating pharmacies has increased almost every year. 35 
Community pharmacy based medication assessment services have subsequently 
expanded across Canada. British Columbia, Alberta, Saskatchewan, New Brunswick, Nova 
Scotia, Prince Edward Island, and Newfoundland and Labrador have established similar 
programs. 3  
 The Saskatchewan Medication Assessment Program (SMAP) was implemented on July 
8th, 2013. 4,5 Under this program, medication assessments are completed by community 
pharmacists for Saskatchewan residents who are 65 years or older and living in their own 
residence, taking five or more chronic medications, or taking an anticoagulant medication listed 
in section 20:12.04 of the Saskatchewan Formulary, or taking a medication listed in the most 
current American Geriatrics Society (AGS) Beers Criteria for Potentially Inappropriate Use in 
Older Adults. 4,5 On April 1st, 2014 the SMAP eligibility criteria was expanded to include people 
who are 65 years or older and living in a personal care home, approved private service home or 
group home. 5 
The SMAP was intended to be a comprehensive medication assessment service, similar 
to the “clinical reviews” described previously. As such, SMAP guidelines require that, at a 
minimum, all the following steps be completed with patients: (1) confirm that no discrepancies 
exist between the patient’s medication list on file in the pharmacy and the medications the 
patient is actually taking; (2) ensure that the patient knows what each medication is for, how to 
take each medication properly; and (3) ensure that the overall medication regimen is appropriate, 
effective and safe, by identifying any drug therapy problems. 4 The provincial drug plan pays the 
pharmacy a medication assessment fee (MAF) of $60 for an initial medication assessment, which 
can be completed with each eligible patient annually. 5 The SMAP also allows for two follow-up 
assessments each year for a follow-up patient assessment fee (FPAF) of $20 per assessment. 5 A 
follow-up assessment is indicated when: the patient is discharged from a hospital or convalescent 
care facility; changes have been made to a patient’s medications; a new medication has been 
added; there is evidence of non-adherence; the patient transfers their medications to another 
pharmacy; or to confirm that a drug therapy problem discovered in the initial medication 
assessment or first follow-up has been resolved. 5 In situations were the pharmacist deems that 
the patient would benefit from compliance packaging, patients who have received a SMAP are 
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eligible for compliance packaging coverage and the provincial drug plan can be billed $25 per 
four weeks of compliance packaging. 5  
 
2.5 Review of the Research on Community Pharmacy-Based Medication Assessment 
Programs 
2.5.1 Evidence for Impact on Patient Outcomes 
Research into medication assessments provided by community pharmacists have looked 
at a variety of different medication assessment services and have measured diverse endpoints. 6-16 
Three systematic reviews have been published that aimed to summarize the evidence for 
pharmacist-led medication assessments. 6-8 The first systematic review looked at the impact of 
medication assessments completed collaboratively between the patients’ general practitioner and 
community pharmacist. 6 Eighty-three articles, including studies from Europe, Canada, Australia, 
New Zealand, and the United States, were included in the review. 6 Most articles did not report 
objective clinical outcomes, however nine articles did report hospital admission rates. 6 Of the 
articles reporting on hospital admission rates, three studies showed a statistically significant 
decrease in hospital admissions, one study showed a statistically significant increase, and the 
remaining studies did not have statistically significant results. 6 Of the three studies showing a 
significant decrease in hospital admission, one showed a 79% reduction in hospitalization 
(hazard ratio = 0.21, 95% CI 0.05 – 0.87) for warfarin associated bleeding in Australian war 
veterans 9, one showed a 45% reduction in hospitalization (hazard ratio = 0.55, 95% CI 0.39 – 
0.77) for heart failure 10, and one showed the overall hospital readmission rate was lower for 
patients receiving the intervention (36.2% vs. 45.5%; adjusted odds ratio = 0.63, 95% CI 0.42 – 
0.94) 11.  The study showing a significant increase in hospitalization, found a 30% increase in 
readmission in patients receiving a medication assessment after initial discharge from hospital 
(rate ratio = 1.30, 95% CI 1.07 – 1.58), but the study was not able to determine why there was an 
increase in readmissions. 12 Aside from these hospital admission outcomes, this systematic 
review found that medication assessments performed collaboratively between community 
pharmacists and general practitioners consistently resulted in a decrease in the number of DTPs, 
improved prescribing, improved quality of life scores, improved MAI scores, increased 
compliance and patient knowledge, improved laboratory values, and positive satisfaction 
outcomes for both clinicians and patients. 6  
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The second systematic review and meta-analysis by Hatah et al aimed to summarize the 
impact of a community pharmacist-led fee-for-service adherence support review or clinical 
medication review. 7 Studies looking at outcomes from unfunded medication assessment services 
that existed only for the purposes of the trial were excluded, because they may not reflect actual 
clinical practice. 7 Thirty-six studies that took place in the USA, UK, Canada, Netherlands, 
Australia, Belgium, and Denmark were selected for inclusion in the review, 21 of which reported 
on the primary outcomes (blood pressure, LDL cholesterol, hospitalization rates and mortality) 
of interest and 32 of which reported on the secondary outcomes (adherence, economic 
implications and quality of life). 7 Several of the studies involved medication assessments (n=30) 
that focused on specific disease states (e.g., asthma, diabetes, hypertension, hyperlipidemia, etc.) 
and the other medication assessments (n=6) were aimed at specific groups of patients (e.g., 
elderly, recently discharged from hospital, and those with polypharmacy). 7 The medication 
assessments took place in either a community pharmacy (42.9%), a community pharmacy or the 
patient’s home (23.8%), at GP clinics/surgeries or community health centres (19%), or at the 
patient’s home (14.3%). 7 Meta-analysis showed that the medication assessments significantly 
improved achievement of target blood pressure (OR 3.50, 95% CI 1.58, 7.75, P=0.002) and LDL 
cholesterol (OR 2.35, 95% CI 1.17, 4.72, P=0.02), but not hospitalization rates (OR 0.69, 95% 
CI 0.39, 1.21, P=0.19) or mortality (OR 1.50, 95% CI 0.65, 3.46, P=0.34). 7 When looking at the 
outcomes separately for medication assessments classified as adherence support reviews or 
clinical medication reviews, a statically significant reduction in hospitalizations was found in 
patients receiving the more in-depth and comprehensive clinical medication review (OR 0.46, 
95% CI 0.26, 0.83, P=0.01), but not the adherence support reviews (OR 0.88, 95% CI 0.59, 1.32, 
P=0.54). 7 In addition, this systematic review found that the medication assessments improved 
patient adherence in 11 of the 19 studies. 7 No conclusions could be made for economic 
implications and quality of life due to a lack of available data in the studies. 7 
The third systematic review and meta-analysis included 32 studies which looked at the 
outcomes of pharmacist-delivered medication reviews that were aimed at optimizing older 
patients’ drug regimens. 8 The review included studies from the United Kingdom, the United 
States, Australia, Canada, Singapore, and one study involving multiple European countries. 8 The 
interventions were delivered in a variety of settings including: hospitals, clinics, primary care 
clinics, community pharmacies, patients’ homes, and a nursing home. 8 The primary outcome 
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was all-cause hospital admissions and the secondary outcomes were mortality and the number of 
drugs prescribed. 8 Seventeen studies reported on all-cause hospital admissions and meta-analysis 
of the results showed the interventions had no significant effect (relative risk (RR) = 0.99; 95% 
CI 0.87, 1.14; P = 0.91). 8 Twenty-two studies reported on mortality and, similarly, meta-analysis 
showed the intervention had no significant effect (RR = 0.96; 95% CI 0.82, 1.13; P = 0.65). 8 A 
meta-analysis of 15 studies providing data on prescribing showed that the interventions reduce 
the number of drugs prescribed (weighted mean difference = -0.48; 95% CI -0.89, -0.07). 8 Only 
one-third of studies measuring quality of life found a benefit of the interventions on quality of 
life and none of them showed a statistically significant benefit. 8  
In Canada, two community pharmacy-based medication assessment pilot programs were 
formally evaluated, the British Columbia Medication Management Program (BCMMP) and the 
Alberta Pharmacy Practice Models Initiative (PPMI). 13,14 The BCMMP pilot project was 
qualitatively evaluated by interviewing pharmacists, physicians, and patients over the phone or in 
focus groups. 13 This pilot program was in place from September 2010 to January 2012. 13 All 
residents of British Columbia were eligible to receive a medication assessment through this 
program as long as they were taking at least one medication. 13 Pharmacists in community 
pharmacies provided the medication assessments. A total of 88 people participated in a focus 
group or interview among all of the stakeholder groups (patients, physicians and pharmacists) 
involved. 13 Benefits of the BCMMP that were recognized by participants of the focus groups 
included: interviewee’s anecdotal perception that the program improved patient’s understanding 
of their medications; providing an integrative review of a patient’s medication profile; patients 
were provided with advice on how to use their medications appropriately to increase 
effectiveness and reduce adverse effects; reviewing over-the-counter (OTC) medications that are 
typically over-looked; increasing pharmacists professional fulfillment; increasing patient loyalty 
to a pharmacy; and providing physicians with updated medication lists. 13 Drawbacks of the 
service were also recognized, including: not being beneficial to patients that were found to lack 
medication issues; potentially jeopardizing physician-patient relationships; potentially increasing 
patient confusion about their medications; increasing demand on pharmacists time; pharmacists 
lacking patient information to make informed recommendations; not being financially feasible 
for pharmacies to provide the service; and physicians not being compensated for the time that 
they were required to spend reviewing and responding to pharmacists recommendations. 13 
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Overall, it was agreed that the BCMMP pilot project had potential to be a valuable service if 
modifications were made addressing the drawbacks identified. 13 
The Alberta PPMI pilot project ran from March 1, 2009 to February 28, 2010. 14 The 
PPMI implemented a medication management model, in which 190 participating pharmacists 
conducted patient assessments, created care plans, evaluated outcomes, and offered additional 
interventions including prescribing (adapting a prescription, prescribing in an emergency, and 
additional authorization to prescribe), administering a drug by injection, chronic disease 
education (diabetes), and recommendations or referrals. 14 A total of 11,326 patients participated 
in the PPMI program and 21,377 DTPs were identified and resolved during the 12 months that 
the PPMI pilot project took place. 14 After the conclusion of PPMI, a program evaluation was 
performed to assess the outcomes. The clinical outcomes were assessed based on the individual 
pharmacist’s assessment of the patient’s condition status from baseline to the most recent follow-
up. 14 The condition status could be classified as unchanged, improved, or declined. 14 Of the 
11,326 patients that received PPMI services, 2,913 had a follow-up completed in which 4,952 
conditions were assessed. 14 Of these conditions 737 were assigned a status of ‘initial’ meaning 
that no interventions had been made, therefore they were not included in the assessment of 
clinical outcomes. 14 For the remaining 4,215 conditions, 1,554 (36.99%) had a status of 
unchanged, 2,388 (55.47%) had a status of improved, and 273 (6.48%) had a status of declined. 14 
Investigators saw this is a positive result and concluded that PPMI had been successful in 
improving patient’s clinical outcomes. 14 The assessment of the clinical outcomes was quite 
subjective and may have suffered significantly from researcher bias, as pharmacists themselves 
were subjectively evaluating the effects that their interventions had on patients’ disease status.  
Part of the program evaluation also included an assessment of patient satisfaction by surveying 
patients who participated in the program. 14 The results were quite positive, with 84% of patients 
agreeing (38.8%) or strongly agreeing (45.2%) that the service they received was just about 
“perfect”. 14 
In an Ontario study, a community pharmacist was hired to provide enhanced medication 
management services, like MedsCheck, to patients within a single community pharmacy. 15 The 
purpose of the study was to determine if the pharmacist could generate enough revenue by 
exclusively working to provide billable services to pay their own salary. 15 The researchers 
measured additional endpoints such as: numbers of DTPs that were resolved and patient’s 
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satisfaction with the service. 15 In a four-month span, from April 4th to July 27th, 2012, the 
pharmacist generated enough revenue to cover his/her full-time salary. 15 A total of 336 patients 
had their medications reviewed, resulting in the resolution of 674 DTPs. 15 Fifty patients were 
chosen randomly to rate their satisfaction with several aspects of the service and the results 
showed that overall patients were very satisfied. 15 
A British Columbia study was also published recently that assessed whether or not the 
provincially funded medication review programs significantly modified prescription drug use for 
the patients who received a review. 16 The investigators used the BC PharmaNet system, the 
provincial drug claims database, to collect data on medication review billings and prescription 
drug dispensations for residents of BC. 16 Patient data was included in the study if the patient had 
received their first medication review between May 1, 2012 and June 30, 2013. 16 Twelve months 
of data was analyzed for each individual included in the study, which was the 12 months 
following their first medication review. 16 Between May 1, 2012 and June 30, 2013, pharmacists 
in BC billed for 266,786 MR-S reviews for 147,770 unique patients and 31,533 MR-PC reviews 
for 16,006 unique patients. 16 The investigators separated the data for patients receiving a MR-S 
and MR-PC to determine if outcomes differed for the two types of reviews and had determined 
immediate changes to the outcomes of interest as well as the trends in the following twelve 
months. 16  
Analysis of the BC PharmaNet data did not provide evidence that the medication 
assessment programs were altering utilization of medication as intended. For example, there was 
a statistically significant increase in total drug expenditure per capita per month for both MR-S 
($7.49 per capita per month; 95% CI, $0.41-$14.60; P = 0.048) and MR-PC ($11.98 per capita 
per month; 95% CI, $3.92-$20.04; P = 0.007) reviews. 16 There were also no significant changes 
in the continuation of many long-term chronic medications, with the exception of a small 
increase in the continuation of statins of 0.52% (95% CI, 0.19%-0.86%; P = 0.005). 16 As well, in 
contrast to what the investigators hoped to find, the number of potential inappropriate 
prescriptions dispensed to patients 65 years and older after their first medication review 
increased (MR-S, 13.32 prescriptions per 1000 patients; 95% CI, 4.09-22.55; P = 0.009; and 
MR-PC, 16.48 prescriptions per 1000 patients; 95% CI, 1.93-31.02; P = 0.035). 16 Investigators 
also found that neither type of medication review helped to decrease the number of visits that a 
patient made to the pharmacy to refill prescriptions or increase the patients loyalty to a particular 
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pharmacy. 16 Overall the investigators concluded that neither the MR-S nor the MR-PC reviews 
had had any meaningful impact on the prescription drug use outcomes that were investigated in 
the study. 16 They suggested that since medication review services can be costly, they needed to 
be modified and evaluated to ensure they are adding value to health care. 16  
 
2.5.2 Barriers and Facilitators to providing medication assessments in community pharmacies 
 Despite the lack of strong evidence to show that community pharmacist-led medication 
assessment services have a clinically meaningful impact on patient health outcomes, the services 
have been frequently implemented across Canada.  Consequently, some information exists 
regarding the barriers and facilitators that have been experienced by pharmacists who have 
attempted to provide these services.  
Researchers from the University of Waterloo conducted a literature review to compile a 
list of the barriers, facilitators and operational requirements that have been identified when 
implementing new pharmacist-led clinical programs and services (such as medication 
assessments) in community pharmacies. 36 The barriers identified included: limited access to 
patient medical records; lack of co-operation with physicians; lack of remuneration; suspected 
misuse/overuse of services; low patient awareness of services; patient privacy concerns; 
pharmacy layouts that do not facilitate the provision of the services; lack of pharmacist time; and 
difficulties with documentation. 36 The facilitators identified that made it easier to provide the 
services included: a blame-free environment; team building and upward communication; 
increased working hour overlaps with multiple pharmacists; external support from upper 
management; interest and motivation of staff; staff understanding of the importance of the 
services; strong communication with physicians and patients; adequate training of staff; re-
evaluation of roles and responsibilities; clear understanding of workflow processes/algorithms; 
and pharmacist knowledge and skills to administer the services. 36   
Additional important operational requirements identified included access to the internet, 
proper software, a private counselling area, access to published research, and access to electronic 
tools/resources. 36 Research specifically considering medication assessment services offered in 
community pharmacies have identified similar barriers and facilitators to those identified for 
community pharmacy services in general. 13,28,37-39 
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The MedsCheck program in Ontario was evaluated to determine barriers that pharmacists 
faced and facilitators that they found helpful when providing the service. 28 Questionnaires were 
mailed out to pharmacists working in Hamilton a few months after the program was 
implemented. 28 The questionnaire was followed up with semi-structured telephone interviews 
intended to delve deeper into the issues identified in the survey. 28 The major barriers that 
pharmacists noted were a lack of time to conduct the assessments and lack of pharmacist overlap 
to cover the dispensary. 28 Pharmacists also cited insufficient reimbursement, interruptions during 
reviews, forgetting to offer service, documentation requirements, lack of a private room, lack of 
patient awareness or interest, and patients thinking a cost was involved, as additional barriers. 28 
When exploring facilitators, pharmacist overlap was found to be a key facilitator. 28 Other 
facilitators included offering reviews on an appointment only basis, advertising, reducing 
documentation, utilizing technicians, increasing physician and patient awareness, availability of 
a private counselling area with access to internet, team work, electronic tools/forms, having 
adequate education and knowledge, and personally inviting patients to participate. 28 
The British Columbia Medication Management Program (BCMMP) pilot project was 
evaluated to determine the perceptions of pharmacists, physicians, and patients. 13 Along with 
exploring benefits and drawbacks of the pilot project, the researchers also identified the 
challenges, or barriers, to providing the service. 13 Pharmacists stated that they had difficulty 
determining which patients would benefit from the service. 13 The computer system used for 
documentation was not integrated into the pharmacy dispensing systems, and consequently 
entering patient data from the medication review was time-consuming. 13 Since documentation 
required so much of the pharmacist’s time, many pharmacists reported that it was often not 
financially feasible to offer the service. 13 Pharmacists also felt that physicians had a negative 
attitude towards the project. 13 This might have been the case, as physicians felt their workload 
increased due to the project, but they were not compensated for their time reviewing the 
pharmacists’ recommendations and responding to patient concerns. 13 
In the United Kingdom (UK), medicines use review (MUR) was introduced in April 2005 
as a way to “establish a picture of the patients understanding and use of prescribed and non-
prescribed medications”. 37 Uptake of the service by pharmacists was lower than expected, so 
researchers developed a questionnaire to explore factors that affected the number of MUR that 
pharmacist performed and their attitudes towards the service. 37 Pharmacists identified the 
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following barriers: doubts about general practitioners’ beliefs that the service was valuable, lack 
of pharmacist time, lack of support staff, unsuitable consultation areas, and lack of reasonable 
financial incentive. 37 
In an effort to identify and potentially eliminate some barriers to providing medication 
assessments, pharmacists in Qatar were given an opportunity to provide their thoughts on the 
MUR service prior to it being implemented in community pharmacy practice. 38 The researchers 
hoped to assess pharmacists’ current knowledge about MUR, their attitudes toward MUR 
services, their willingness to provide MUR, and the availability of facilities to provide the MUR 
services. 38 The questionnaire was distributed to a random sample of 220 community pharmacists 
in Qatar in December 2012. 38 One hundred twenty-three (56%) pharmacists responded to the 
survey, but only 116 (53%) responses were usable. 38 It was found that pharmacists were quite 
knowledgeable about MUR, with a mean total knowledge score (± SD) of 71.4 ± 14.7%. 38 
Gender, age, highest pharmacy degree obtained, years of experience, and hours worked per 
week, had no significant effect on knowledge scores, however attitudes towards practice change 
had a significant effect on knowledge scores. 38 Pharmacists who indicated that they aspired to be 
role models had higher mean knowledge scores than those who indicated that they were resistant 
to new ways of working (76.1% vs. 55.0%; p = 0.032). 38 
The majority of pharmacists who completed the questionnaire had positive attitudes 
towards MUR services. 38 For example, 96.5% agreed that MUR is a great opportunity for an 
extended pharmacists’ role and 95.7% agreed that MUR are an excellent use of pharmacists’ 
skills. 38 It is interesting to note that 41.7% of the respondents indicated that they believed a lack 
of access to medical records reduces the benefits of MUR services. 38 Slightly more than half 
(57.7%) felt that there was enough time for MUR services in their practice. 38 When asked about 
their willingness to provide MUR services, 87% agreed that they were willing to incorporate 
these services within their daily practice. 38 Only 25% of the respondents agreed that there was a 
screened area available in the community pharmacy to provide MUR services, indicating that 
this would likely be a significant barrier to providing MUR services in Qatar. 38 Even fewer 
respondents, 16.4%, agreed that they had sufficient training to provide MUR services, showing 
that a lack of knowledge and confidence in their ability to provide MUR may also be significant 
barriers to providing MUR services. 38 The overwhelming majority of pharmacists, 95.6%, 
agreed that training programs to orient and educate pharmacists should be conducted by 
 19 
universities and the Supreme Council of Health before implementing MUR service in Qatar. 38  
Pharmacists who participated in the General Practitioner-Pharmacist Collaboration 
(GPPC) study in Auckland, New Zealand, were asked to participate in semi-structured interviews 
to identify potential barriers to community pharmacists providing clinical medication reviews. 39 
The pharmacists who were interviewed expressed that they did not think there was a clear 
mandate from general practitioners or the government for pharmacists to take on the role of 
performing clinical medication reviews. 39 The pharmacists also felt that providing medication 
reviews was not a legitimate role that fit into the normal dispensing activity in a community 
pharmacy. 39 Many of the pharmacists saw it as a nice thing to do, but not a priority. 39 The 
pharmacists also struggled with feelings about the adequacy of their clinical knowledge and 
skills to provide medication reviews. 39 Lastly, the pharmacists questioned the effectiveness of 
the service; many pharmacists citied that they had not received feedback on the 
recommendations they had made and did not know if their work was useful. 39  
 
2.6 Why should the Saskatchewan Medication Assessment Program (SMAP) be evaluated? 
Based on the previous summary of the literature, there exists a significant amount of 
research regarding the impact of community pharmacy based medication assessment programs 
on patients, and also regarding the barriers and facilitators to integrating these programs into an 
existing community pharmacy team.  However, recently community pharmacists in Canada 
became the target of a large CBC News Marketplace investigation, which questioned the quality 
of service that community pharmacists were providing to their patients and the potential risk to 
patient safety. 40 On March 24, 2015 CBC News published an article titled “Medication reviews 
may miss patients who need them”. 40 The opening argument for this article stated that 
“Medication reviews, which are publicly funded safeguards designed to make sure people are 
taking prescription drugs correctly, are not always performed properly or reaching the people 
who need them most”. 40 The author claimed Canadian pharmacists report they are under pressure 
in recent years to do as many medication assessments as possible and in some cases even have a 
quota that they are expected to achieve. 40 It was suggested that this recent pressure that has now 
been put on pharmacists to offer these services might be causing them to perform poor quality 
assessments and choose patients with fewer medications that are less complicated so that the 
assessments can be completed very quickly. 40 If these allegations are accurate, medication 
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assessment services in Canada may not be achieving the same outcomes as in previous years.  It 
is therefore possible that these recent changes and pressures to the health system landscape in 
Canada may have impacted the ability of community pharmacists to provide quality medication 
assessment services, making it difficult to translate the evidence from previous studies to the 
SMAP in Saskatchewan.    
In addition, the SMAP is a new medication assessment service and has yet to be 
evaluated and it cannot be assumed that evidence from other similar programs will translate 
directly to this unique program. Consequently, it is important to evaluate the SMAP to determine 
if it is meeting the intended purposes. 
The SMAP was intended to fulfill seven purposes as outlined in the guidance document 
prepared by the Drug Plan and Extended Benefits Branch of the Saskatchewan Ministry of 
Health: (1) to provide safe and effective medication therapy to seniors living in the community; 
(2) to improve patient safety and patient outcomes; (3) to prevent drug related problems, 
emergency room visits and hospitalizations; (4) to reduce duplication and or wastage of 
medication; (5) to optimize medication adherence; (6) to provide support to seniors living in the 
community that will allow them to age within their own home; and (7) to assist the patient and/or 
caregiver with appropriate and cost-effective medication administration. 4,5 
From June 30th, 2013 to June 30th, 2016 a total of $4,585,143 was billed by community 
pharmacies for SMAP program services: $1,810,000 for initial Medication Assessments (MAF), 
$132,060 for Follow-up assessments (FPAF), and $2,643,083 for Compliance Packaging. 41 
Community-based, government funded programs like the SMAP can be quite expensive and time 
consuming, but also have the potential to offer great benefits.  Since funding available for health 
and other services is limited, it is important that research is performed to determine if the 
programs and services that are offered are able to provide patient benefit. 
 
 
 
 
 
 
 
 21 
 
 
CHAPTER 3 
STUDY PURPOSE 
 
The purpose of this study is to explore pharmacists’ experiences with, and perceptions of, 
the SMAP.  Since community pharmacists are directly involved in interacting with patients to 
complete the medication assessments, they are in an ideal position to make judgments pertaining 
to whether or not the program is meeting purposes, identify the barriers and facilitators that 
pharmacists are dealing with in their practice when trying to implement the SMAP, and make 
suggestions for improvements that could be made to the program in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
 
CHAPTER 4 
RESEARCH OBJECTIVES 
 
1. Determine the extent to which pharmacists believe they are fulfilling the purposes of the 
Saskatchewan Medication Assessment Program as outlined in the guidance document prepared 
by the Drug Plan and Extended Benefits Branch of the Saskatchewan Ministry of Health. 
2. Describe pharmacists’ perceptions of the barriers and facilitators to fulfilling the purposes of 
the Saskatchewan Medication Assessment Program as outlined in the guidance document 
prepared by the Drug Plan and Extended Benefits Branch of the Saskatchewan Ministry of 
Health. 
3. Determine strategies pharmacists would like to see implemented to assist them to fulfill the 
purposes of the Saskatchewan Medication Assessment Program as outlined in the guidance 
document prepared by the Drug Plan and Extended Benefits Branch of the Saskatchewan 
Ministry of Health. 
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CHAPTER 5 
METHODS 
 
5.1 Overview of Research Methods 
The methodology used for this research was an embedded mixed methods design. 42 
Mixed methods research involves the use of both qualitative and quantitative data collection 
methods. 42 An embedded mixed methods design refers to research that primarily utilizes one of 
the data collection types (qualitative or quantitative) and embeds a smaller portion of the other 
type into the primary type as a means to supplement the primary data. 42 A common example of 
an embedded mixed methods design is a largely quantitative survey in which some open-ended 
questions are included to collect additional qualitative data, as was done in this study. 42 
This study utilized an online, self-administered questionnaire to survey pharmacists 
currently practicing in a community pharmacy setting in Saskatchewan. A survey has been 
defined as “a system for collecting information from or about people to describe, compare, or 
explain their knowledge, attitudes, and behavior”. 43 Since the objectives of this research project 
involved determining pharmacists’ beliefs and perceptions regarding the research objectives, a 
survey was selected as the primary research method.   
Survey questions can be used in research instruments such as self-administered 
questionnaires and face-to-face or telephone interviews. 43 In the case of a self-administered 
questionnaire, the respondent fills out the questionnaire individually. 44 In addition, an online 
questionnaire can be distributed to a large group of people for a low cost.  Since it was feasible to 
distribute a self-administered online questionnaire to a large portion of the population of 
community pharmacists in Saskatchewan (via the Pharmacy Association of Saskatchewan), this 
is the specific method that was used to implement the survey.   
 
5.2 The Sample 
All licensed pharmacists who self-declared that they were practicing in a community 
pharmacy setting anywhere in Saskatchewan (on a full, part-time or casual basis) at the time of 
data collection, were eligible to participate in the study.  Pharmacists were only excluded if they 
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did not practice in a community pharmacy in Saskatchewan.  The online questionnaire was 
distributed to all Saskatchewan pharmacists with a Pharmacy Association of Saskatchewan 
(PAS) membership through the PAS email database.  PAS is the professional advocacy body for 
Saskatchewan pharmacy professionals and membership amongst practicing pharmacists is 
voluntary. 45 PAS agreed to distribute the questionnaire on our behalf, since the SMAP is a 
program that they created. At the time of the survey distribution (January 26th, 2016), PAS had 
1295 practicing members 41, which includes 82.6% of the 1568 licensed pharmacists in 
Saskatchewan (according to the Saskatchewan College of Pharmacy Professionals (SCPP), who 
license pharmacists in the province). 46 The SCPP was originally approached to distribute the 
survey, as their database contains a complete list of all practicing pharmacists in Saskatchewan; 
however, SCPP preferred that PAS distribute the survey since the SMAP is a program that was 
created by PAS.  
PAS members can voluntarily declare a ‘primary practice site’ when they purchase their 
membership, and this data is included in the PAS member database.  However, all PAS members 
(regardless of their self-declared primary practice site) were invited to participate in the study.  If 
only PAS members who self-declared ‘community pharmacy’ as their primary practice had been 
invited, the survey would have missed pharmacists who chose not to declare their primary 
practice site, those who moved to community pharmacy since declaring, and those who work 
part-time in community pharmacy.  The following statement was included in the survey 
invitation email to encourage the correct pharmacists to completed the questionnaire: “Please fill 
out this questionnaire only if you currently practice in the community pharmacy setting on a full, 
part-time or casual basis”. (See Appendix A) 
 
5.3 Questionnaire Content 
The questionnaire (see Appendix C) contained 53 items.  Part A asked pharmacists if 
they believe the SMAP is fulfilling the intended purposes, part B asked pharmacists to consider 
the facilitators and barriers that may help or hinder them in providing a medication assessment, 
and part C asked demographic questions. In addition, three initial questions were included (prior 
to Part A) for the purposes of determining if the respondent was familiar with the SMAP, the 
extent of previous experience the respondent had had with the program, and the extent to which 
the pharmacy they work in participated in the program.  There was a possibility that some 
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community pharmacists were not aware of the SMAP, therefore one of the initial questions asked 
whether or not the respondent was familiar with the program.  For those who indicated that they 
were not familiar with the SMAP, parts A and B would be skipped and only demographic 
information would be collected.  Pharmacists indicating that they were not familiar with the 
SMAP would not be asked the questions in parts A and B, because they would not have 
developed opinions about the program necessary to answer the questions; consequently the data 
would be meaningless and it would be a frustrating experience for the respondent.  For 
pharmacists who indicated that they were familiar with the program, but have not personally 
completed an assessment through the SMAP, questions regarding personal experience with the 
SMAP were skipped.  
 
5.4 Questionnaire Development Methodology 
The questionnaire was developed after reviewing the literature regarding previous 
evaluations of medication assessment programs, as well as documentation from the 
Saskatchewan Ministry of Health regarding SMAP procedures and guidelines. 4,5 The initial draft 
of the questionnaire was developed by the primary investigator in collaboration with her faculty 
supervisor. The questionnaire was also revised based on feedback from primary investigator’s 
supervisory committee members, which included three faculty members within the College of 
Pharmacy and Nutrition. Upon review by the committee members, the primary investigator 
drafted a second version of the questionnaire that was sent to PAS, SCPP, and the Saskatchewan 
Ministry of Health for comments, which were incorporated into a third draft of the questionnaire.  
 The questionnaire was subsequently pilot tested by ten pharmacists who were not 
working in a community pharmacy setting and were therefore not eligible to be involved in the 
study. These pharmacists were asked to comment regarding questionnaire readability, 
convenience, misspelled words, sentences that were difficult to understand, and unknown terms. 
They were also asked to comment on issues such as font size or type, ease of use of the online 
questionnaire, any problems that were encountered while trying to complete the questionnaire, 
and the length of time it took them to complete the questionnaire.  Comments made by 
individuals were carefully considered, and the format and content of the questionnaire was edited 
and revised.  
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Finally, representatives of PAS reviewed the final questionnaire to ensure that it met their 
policies and procedures regarding electronic communications distributed to its members. The 
representatives from PAS did not suggest any further edits at the time of the final review. 
 
5.5 Distribution of the Questionnaire and Collection of Data 
 The questionnaire was distributed to pharmacists on January 26th, 2016 via an email 
communication from PAS that included a link to the online questionnaire that was created using 
FluidSurveysTM. 47 Respondents were allowed skip questions that they did not want to answer and 
they were also able to go back and change answers to questions at any time before submitting the 
completed questionnaire; however respondents were not presented with a summary of their 
responses at the end of the questionnaire.  
 Respondents could potentially answer the survey more than once, as the anonymous 
settings that were used did not allow for security against this. Part of the anonymous settings 
included that the IP address would not be recorded.  
 The first email contact, on Tuesday, January 26th, 2016, included a link to the online 
questionnaire along with an explanation of the research being conducted and the contact 
information of the principal investigator for those with further questions (See Appendix A: 
Invitation).  One email reminder was sent two weeks following the initial invitation, on Tuesday, 
February 9th, 2016 (See Appendix B: Reminder).  The questionnaire was closed four weeks 
following the initial invitation, on Tuesday, February 23rd, 2016.  
 A small incentive was included to encourage participation. The first fifty respondents 
were offered a $10 Tim Horton’s gift card and all respondents were entered into a draw for a 
chance to win one of eight $250 gift cards.  
 
5.6 Data Analysis  
5.6.1 Statistical Analysis of Closed-ended and Likert-type Questions 
Data from closed-ended and Likert-type questions (i.e., quantitative data) was exported 
from FluidSurveysTM to SPSS (Version 23). Descriptive statistics were used to characterize the 
responses to all of these questions.  
 Prior to performing any analysis, comparisons were planned between selected 
demographic data and Likert-scale questions based on relationships that were suspected to exist. 
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The specific questions that were compared using statistical analysis are shown in Table 1 along 
with the reasoning for suspecting a relationship might exist.  
It has been disputed among researchers whether Likert data should be analyzed as ordinal 
or interval data. 48-51 Some take that position that Likert data should be treated as ordinal because 
the intervals between response categories should not be assumed to be equal. 48,49 Treating Likert 
data as ordinal data means that analysis can only be done using non-parametric statistics. 48 On 
the other side of the argument, some researchers point out that parametric tests, like Analysis of 
Variance (ANOVA), are more powerful and sensitive than non-parametric tests. 49-51 Norman 
concluded that empirical literature has shown, “[p]arametric statistics can be used with Likert 
data, with small sample sizes, with unequal variances, and with non-normal distributions, with 
no fear of “coming to the wrong conclusion”. 50  
For this research, given the arguments presented in the literature for analyzing Likert 
data, one-way ANOVA was used to identify if there were statistically significant differences 
between specific respondent groups and how they responded to various Likert-type questions. 
One-way ANOVA, “is used to determine whether there are any statistically significant 
differences between the means of three or more independent (unrelated) groups”. 52 Since a 
statistically significant one-way ANOVA result only shows the researcher that there is a 
significant difference between at least two groups, post hoc tests are used to determine which 
specific groups differ. 52 When statistically significant relationships were found, the Tukey’s 
honestly significant difference (HSD) post hoc test was used to determine where the differences 
occurred. 52 
Table 1: Questions tested using Analysis of Variance (ANOVA) 
Questions: Reasons for Comparing: 
Indicate the number 
of SMAP medication 
assessments that you 
personally complete 
in a typical month. 
I enjoy performing 
SMAP assessments. 
It is suspected that respondents who 
agree/strongly agree that they enjoy 
performing SMAP assessments will indicate 
that they perform more SMAP assessments 
than those who do not because they may be 
more likely to promote the service to patients 
and seek out opportunities to provide SMAP 
assessments.  
Sometimes I have 
trouble identifying drug 
related problems when 
completing a SMAP 
It is suspected that respondents who agree or 
strongly agree that they have trouble 
identifying drug related problems due to lack 
of information, will indicate that they 
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assessment because I do 
not have enough 
information about the 
patient’s medical 
history. 
perform fewer SMAP assessments because 
they are likely to be less comfortable offering 
the service when they feel they do not have 
access to necessary information. 
When completing a 
SMAP assessment I 
feel comfortable 
making 
recommendations to 
physicians. 
It is suspected that respondents that disagree 
or strongly disagree that they feel 
comfortable making recommendations to 
physicians, will indicate that they perform 
fewer SMAP assessments to avoid the 
potential of having to contact the physician 
about suspected drug related problems.  
How many years have 
you been a licensed 
pharmacist? 
I am confident in my 
ability to identify drug 
related problems when I 
perform SMAP 
medication 
assessments. 
It is suspected that pharmacists who have 
been in practice for a long time, who may 
have outdated clinical knowledge and no 
formal education on performing medication 
assessments or those who have recently been 
licensed with little practice experience, will 
be less likely to indicate that they are 
confident in their ability to identify drug 
related problems, than those who have some 
practice experience combined with fairly up 
to date clinical knowledge and some formal 
education on performing medication 
assessments during their undergraduate 
degree. 
When you are 
completing a SMAP 
assessment, how often 
do you contact the 
physician to request 
additional information 
from the patient’s 
chart? 
We suspected that pharmacists with fewer 
years in practice would be more likely to 
indicate that they contact that physician to 
request additional information from the 
patient’s chart more often, because 
collaborative practice and sharing of 
information is encouraged in current 
undergraduate pharmacy programs. 
When completing a 
SMAP assessment I 
feel comfortable 
making 
recommendations to 
physicians. 
It is suspected that pharmacists who have 
been in practice for a long time, who may 
have outdated clinical knowledge and no 
formal education on performing medication 
assessments or those who have recently been 
licensed with little practice experience, will 
be less likely to indicate that they are 
comfortable making recommendations to 
physicians, than those who have some 
practice experience combined with fairly up 
to date clinical knowledge and some formal 
education on performing medication 
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assessments during their undergraduate 
degree. 
What is the 
population of the 
community where you 
pharmacy is located? 
The SMAP encourages 
collaboration between 
pharmacists and 
physicians. 
It is suspected that in rural areas the 
physicians and pharmacists are already 
engaged in collaborative relationships and 
would not indicate that the SMAP encourages 
this further. 
Table 1: A summary of the seven planned comparisons between the responses to selected questions and the reasons 
for choosing to make these comparisons. 
 
5.6.2 Comparison of the number of SMAP assessments performed by respondents with the 
barriers and facilitators that the respondents identified as being significant 
In an attempt to determine if the most popular barriers and facilitators selected by 
respondents had an effect on the number of SMAP assessments that respondents indicated that 
they performed in a typical month, a comparison between these data was conducted. Using 
Pearson’s Chi-Square, a comparison between whether or not respondents had selected the most 
popular barriers and facilitators and the number of SMAP assessments the respondents had 
indicated that they performed in a typical month was performed. Pearson’s Chi-Squared test is 
used to determine if there is an association between two categorical variables. 53 In this case the 
two categorical variables were: (1) if the respondent had ‘selected’ or ‘not selected’ the barrier or 
facilitator in question, and, (2) if the respondent indicated that they completed ‘zero’, ‘1 to 5’, or 
‘6 to 21+’ SMAP assessments in a typical month.  
 
5.6.3 Non-response Bias  
 Two discreet methods were used to assess for non-response bias. The first was a 
comparison of the early and late respondents, defined by those who responded before the 
reminder sent on February 9th, 2016 and those who responded after the reminder. To determine if 
the early and late respondents answered the survey questions similarly, the responses to each 
multiple choice and Likert-type question were compared using the Mann-Whitney U test, a non-
parametric test that can be “used to compare differences between two independent groups when 
the dependent variable is either ordinal or continuous, but not normally distributed”. 54 In this 
case the two independent groups were the early responders and late responders and the 
dependent variables were the respondent’s answers to the survey questions. The theory behind 
this method is that respondents who are more resistant to responding (i.e., late respondents) are 
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more similar to non-respondents than they are to early respondents. 55,56 A statistically significant 
result would indicate the potential for non-response bias. This method is limited as the late 
respondents are still respondents and thus could differ from the non-respondents, however it is 
used in studies when a survey of non-respondents is not feasible. 55,56 
 The second method used to assess for non-response bias was a comparison of the 
demographic characteristics of the respondents to the demographic characteristics of the entire 
population of pharmacists in Saskatchewan. Data from the Canadian Institute for Health 
Information (CIHI) report, Pharmacists, 2014 was visually compared to the demographic data 
collected in the questionnaire. 57 The CIHI report summarizes the demographics, education and 
employment status of the pharmacist workforce in Canada, broken down by province, during the 
years of 2010 to 2014. 57 The data from 2014 is used for the comparison, as it is the most recent 
data available. The characteristics that were compared between the two populations were the 
demographic characteristics (e.g. pharmacy owner/manager, staff pharmacist, male, female, etc.) 
The theory behind this approach is that if the demographic characteristics of the respondents and 
the entire population are similarly distributed, the respondents are more likely to be 
representative of the entire population. 56 A limitation of this approach is that the demographics 
of the pharmacists are not necessarily the focus of the research. 56 In the case of this research, 
pharmacists’ attitudes toward the SMAP were the main focus of the research and attitudes of 
pharmacists may have little to do with their demographic characteristics. 
 
5.6.4 Content Analysis of Open-ended Questions 
Answers to open-ended, free-text questions (i.e., qualitative data) were analyzed using a 
technique known as content analysis. It has been defined as “a systematic, replicable technique 
for compressing many words or text into fewer content categories based on explicit rules of 
coding”. 58 To minimize researcher bias, the content analysis was performed by three individuals; 
Dr. Derek Jorgenson, a clinical pharmacist and faculty member at the University of 
Saskatchewan; Katherine Lysak, a hospital pharmacist and graduate student at the University of 
Saskatchewan; and Krysta Currie, the primary investigator who is a community pharmacist and 
graduate student at the University of Saskatchewan. Dr. Derek Jorgenson and Katherine Lysak 
both had previous experience with content analysis.  
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The analyzers were given step-by-step instructions (Appendix D), which were adapted 
from Developing a Questionnaire, to complete the content analysis as well as a printed copy of 
the written responses to the open-ended questions. 59 Each analyzer individually read through the 
responses to select the main concepts (or themes). The three analyzers subsequently met on two 
separate occasions to come to a consensus on the main concepts (or themes) that emerged from 
the data, and also to attempt to categorize the main concepts (or themes). The main concepts (or 
themes) and categories were refined until the analyzers were satisfied with the list of categories 
and that each concept fit into a category or it was decided that it could not be categorized.  
Following this content analysis an external audit was performed to enhance the 
trustworthiness and credibility of the findings. As part of the external audit process, a researcher 
who has not been involved in the research process examines the documentation of the content 
analysis process and the findings to determine if the findings could be logically interpreted from 
the data. 60,61 Katherine Ford, a Registered Dietician and graduate student at the University of 
Saskatchewan with previous experience with qualitative analysis, acted as the external auditor. 
Katherine was given the content analysis guidelines used by the analyzers, a copy of the answers 
to the open-ended questions as well as the copies used by the original analyzers (that included 
their notes and highlighting), a list of the nine main themes, and the summary of the qualitative 
analysis results. Katherine was asked to determine if the themes developed by the analyzers 
aligned with the responses to the open-ended questions.  
 
5.7 Ethics 
 The Behavioural Research Ethics Board at the University of Saskatchewan approved the 
protocol on January 11th, 2016 (BEH# 15-378). The survey was anonymous and aside from a 
minimal time commitment to complete the questionnaire, the research project posed little risk to 
participants.  Prior to responding, participants were informed about the research project 
including: who was carrying out the research, the sponsorship provided, the purpose of the 
research, and the level of confidentiality/anonymity guaranteed (See Appendix A: Invitation).  A 
statement regarding voluntary participation and the ability to skip questions was also included.  
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CHAPTER 6 
RESULTS 
 
6.1 Response Rate 
A total of 1124 PAS members were sent an email inviting them to participate in the 
survey and 228 chose to participate by answering at least one question, resulting in an overall 
response rate of 20.3%. Not all participants answered every question; therefore, response rates 
are also reported for each individual survey question. During data analysis it was decided to 
include all responses regardless of how few questions were answered by the respondent. As well, 
some questions were only presented to respondents depending on their responses to previous 
questions, making the number of respondents to those questions appear significantly lower than 
the 228 total respondents.   
 
6.2 Participant Demographics 
The majority of the respondents indicated that they were staff pharmacists (n=128/199, 
64.3%) and worked between 31 to 40 hours in a community pharmacy setting in a typical week 
(n=115/200, 57.5%). Respondents had varying years of experience as licensed pharmacists, with 
the greatest proportion of respondents indicating they had been licensed between 11 to 20 years 
(n=48/198, 24.2%). The respondents were distributed between rural, small city and large city 
practice sites, with the largest proportion indicating they practiced in a large city (n=83/200, 
41.5%). Most respondents indicated that the number of prescriptions filled per day at their 
pharmacy was between 100 to 200 (n=78/199, 39.2%) or 201 to 300 (n=56/199, 28.1%). One 
hundred thirty-two of the 228 respondents (57.9%) indicated they had completed additional 
training/education. Detailed demographic information of respondents is presented in Table 2.  
Table 2: Participant Demographics 
Characteristic: Number (228): Percentage: 
Position Pharmacy Owner 26 13.1% 
Pharmacy Manager 36 18.1% 
Staff Pharmacist 128 64.3% 
Relief/Casual Pharmacist 9 4.5% 
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Missing 29  
Hours worked in 
community 
pharmacy in a 
typical week 
Less than 10 hours 8 4.0% 
10-20 hours 11 5.5% 
21-30 hours 22 11.0% 
31-40 hours 115 57.5% 
More than 40 hours 44 22.0% 
Missing 28  
Gender Male 44 22.0% 
Female 152 76.0% 
Prefer not to answer 4 2.0% 
Missing 28  
Years as a 
licensed 
pharmacist 
1 year or less 20 10.1% 
2 – 5 years 40 20.2% 
6 – 10 years 33 16.7% 
11 – 20 years 48 24.2% 
21 – 30 years 36 18.2% 
More than 30 years 21 10.6% 
Missing 30  
Population of the 
community 
where pharmacy 
is located 
Rural (<5,000) 63 31.5% 
Small city (5,000 – 100,000) 54 27.0% 
Large city (Saskatoon or Regina) 83 41.5% 
Missing 28  
Classification of 
pharmacy  
Independent/Banner 92 46.7% 
Franchise 31 15.7% 
Chain/Supermarket/Mass 
merchandiser 
74 37.6% 
Missing 31  
International/ 
Canadian 
Gradate 
International pharmacy graduate 8 4.0% 
Canadian pharmacy graduate 191 96.0% 
Missing 29  
Number of 
prescriptions 
filled in a typical 
day 
< 100 22 11.1% 
100 – 200 78 39.2% 
201 – 300 56 28.1% 
> 300 43 21.6% 
Missing 29  
Additional 
training/ 
education 
Residency (ACPR) 3 1.3% 
ADAPT Certificate in Patient Care 
Skills (CphA) 
15 6.6% 
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completed CPhA Medication Review Services 
Program 
12 5.3% 
Certified Diabetes Educator (CDE) 10 4.4% 
Certified Respiratory Educator (CRE) 11 4.8% 
Certified Geriatric Pharmacist 2 0.9% 
Advanced Method Certification 
(Immunization and Injection Training) 
114 50.0% 
Board Certification in United States 
(BPS) 
0 0% 
Post baccalaureate PharmD 0 0% 
Masters Degree 4 1.8% 
PhD Degree 1 0.4% 
Other* 13 5.7% 
Table 2: A summary of the demographic information collected from the respondents. 
*Other: The 13 respondents who indicated that they had completed other training besides those included in the list 
indicated they had received the following training: CPhA Lab Tests Interpretation, Associate of the Trinity College 
of Music, Resptrek and Asthmatrek, CAE, PACT training, Minor Ailments Prescribing, BSc Food Science and 
Nutrition, Travel Medicine Certificate, Sigvaris training, CBT-I training, BSc Physiology and MSc Nutrition.  One 
respondent also included that he or she was almost finished immunization training and another indicated that he or 
she was working on ADAPT.  
 
6.3 Degree of Experience with the Saskatchewan Medication Assessment Program 
Of the 227 respondents who answered the first question regarding previous involvement 
with the SMAP, 207 (91.2%) indicated that they had completed at least one medication 
assessment through the SMAP (Figure 1). The remaining 20 respondents (8.8%) indicated that 
they were aware of the SMAP, but have never completed a medication assessment (Figure 1). 
There were no respondents who indicated that they had never heard of the SMAP.  
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Figure 1: The number of respondents who indicated their level of involvement with the Saskatchewan Medication 
Assessment Program based on the three response options. Total number of responses = 227. 
 
Of the 207 pharmacists who had completed at least one SMAP medication assessment, 
the majority, 164 (79.2%), indicated that they personally complete between one and five SMAP 
medication assessments in a typical month (Figure 2).  
  
Figure 2: The number of respondents who indicated the number of SMAP medication assessments they personally 
complete in a typical month based on the response ranges provided. Total number of responses = 207. 
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 When asked how many SMAP assessments all pharmacists at the respondent’s pharmacy 
completed in a typical month, the most common answer, given by 102 of the 222 respondents 
(45.9%), was between one and five assessments (Figure 3).  
 
Figure 3: The number of respondents who indicated the number of SMAP medication assessments complete in a 
typical month in the pharmacy where they work based on the response ranges provided. Total number of responses 
= 222. 
 
6.4 Does the SMAP Fulfill the Stated Purposes? 
In part A of the questionnaire, pharmacists were asked to rate their levels of agreement 
with statements relating to the seven purposes of the SMAP that were laid out by the 
Saskatchewan Ministry of Health. The first purpose of the SMAP is: To provide safe and 
effective medication therapy to seniors living in the community. This was divided into two 
statements in the questionnaire: Assessments provided through the SMAP improve medication 
safety for seniors and Assessments provided through the SMAP ensure that seniors are taking the 
most effective medication therapy.  Of the 214 pharmacists responding to the first statement, 192 
(89.7%) indicated that they agreed or strongly agreed with the statement (Figure 4). A similar 
response was observed with the second statement, with 179 (83.6%) of the 214 respondents 
indicating that they agreed or strongly agreed (Figure 5). 
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Figure 4: The number of respondents who indicated their level of agreement that SMAP assessments improve 
medication safety for seniors. Total number of responses = 214. 
 
 
Figure 5: The number of respondents who indicated their level of agreement that SMAP assessments ensure that 
seniors are taking the most effective medication therapy. Total number of responses = 214. 
 
The second purpose of the SMAP is to improve patient safety and patient outcomes. This 
was assessed using the statement: Seniors who receive a SMAP assessment are more likely to 
have improved health outcomes compared with seniors who do not receive an assessment. One 
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hundred sixty-one of the 214 respondents (75.2%) to this question agreed or strongly agreed with 
this statement (Figure 6).  
  
Figure 6: The number of respondents who indicated their level of agreement that seniors who receive SMAP 
assessments are more likely to have improved health outcomes compared with seniors who do not receive an 
assessment. Total number of responses = 214. 
 
The third purpose of SMAP is to prevent drug related problems, emergency room visits 
and hospitalizations. Three separate questionnaire items were created to evaluate this SMAP 
purpose: (1) Assessments provided through the SMAP prevent drug-related problems for seniors; 
(2) An assessment completed through the SMAP is likely to decrease the incidence of emergency 
room visits for seniors; and (3) An assessment completed through the SMAP is likely to decrease 
the incidence of hospitalizations for seniors. Of the 214 pharmacists that responded to the 
statement regarding drug-related problems, 190 (88.8%) agreed or strongly agreed (Figure 7). 
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Figure 7: The number of respondents who indicated their level of agreement that SMAP assessments prevent drug 
related problems for seniors. Total number of responses = 214. 
 
Overall pharmacists were not as confident that SMAP assessments reduce emergency 
room visits and hospitalizations. A small majority, 117, of the 204 respondents (57.3%) agreed 
or strongly agreed that an assessment completed through the SMAP was likely to decrease the 
incidence of emergency room visits for seniors, however, many (n=81/117 (39.7%)), indicated 
that they were not sure (Figure 8). Responses were similar to the question related to 
hospitalization rates, with 66 (32.5%) of the 203 respondents indicating they were not sure that 
an assessment completed through the SMAP was likely to decrease the incidence of 
hospitalizations for seniors (Figure 9). 
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Figure 8: The number of respondents who indicated their level of agreement that SMAP assessments decrease the 
incidence of emergency room visits for seniors. Total number of responses = 204. 
 
  
Figure 9: The number of respondents who indicated their level of agreement that SMAP assessments decrease the 
incidence of hospitalizations for seniors. Total number of responses = 203. 
 
The fourth purpose of the SMAP is to reduce duplication and or wastage of medication. 
This was assessed using two questionnaire items: (1) SMAP assessments reduce duplication of 
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medication therapy for seniors, and, (2) Providing SMAP assessments to seniors reduces 
medication wastage. One hundred ninety-seven of the 202 respondents (97.5%) agreed or 
strongly agreed that SMAP assessments reduce duplication of medication therapy for seniors 
(Figure 10).  
 
  
Figure 10: The number of respondents who indicated their level of agreement that SMAP assessments reduce 
duplication of medication therapy for seniors. Total number of responses = 203. 
 
Out of 203 respondents, 171 (84.2%) agreed or strongly agreed that providing SMAP 
assessments to seniors reduces medication wastage (Figure 11).  Only four respondents (2%) 
disagree with this statement and no one indicated that they strongly disagreed.  
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Figure 11: The number of respondents who indicated their level of agreement that providing SMAP assessments to 
seniors reduces medication wastage. Total number of responses = 203. 
 
 The fifth purpose of the SMAP is to optimize medication adherence.  Respondents were 
asked to indicate their level of agreement with the statement: Seniors who receive an assessment 
through the SMAP have improved medication adherence following the assessment.  One hundred 
fifty-two of the 203 respondents (74.9%) indicated that they agreed or strongly agreed with this 
statement (Figure 12).  
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Figure 12: The number of respondents who indicated their level of agreement that seniors who receive an SMAP 
assessment have improved medication adherence following the assessment. Total number of responses = 203. 
 
 The sixth purpose of the SMAP is to provide support to seniors living in the community 
that will allow them to age within their own home. Respondents were asked for their level of 
agreement with the following statement: SMAP assessments provide support to seniors living in 
the community that will allow them to age within their own home.  Of the 203 respondents to this 
question, 133 (65.5%) indicated that they agreed or strongly agreed with the statement (Figure 
13).  A large portion of respondents, 59 (29.1%), indicated that they were not sure if SMAP 
assessments provided support to allow seniors to age within their own home (Figure 13).  
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Figure 13: The number of respondents who indicated their level of agreement that SMAP assessments provide 
support to seniors living in the community that will allow them to age within their own home. Total number of 
responses = 203. 
 
The last purpose of the SMAP is: To assist the patient and/or caregiver with appropriate 
and cost-effective medication administration.  Respondents were presented with the statement: 
SMAP assessments provide an opportunity for pharmacists to assist their patients and/or 
caregivers in administering their medications appropriately.  One hundred ninety-six of the 203 
respondents (96.6%) to this question agreed or strongly agreed with the statement (Figure 14).   
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Figure 14: The number of respondents who indicated their level of agreement that SMAP assessments provide an 
opportunity for pharmacists to assist their patients and/or caregivers in administering their medications 
appropriately. Total number of responses = 203. 
 
6.5 Pharmacists’ Personal Experiences with the SMAP 
Respondents were asked additional questions in part A relating to their personal 
experiences with the SMAP.  The 207 pharmacists who indicated that they had completed at 
least one SMAP medication assessment were asked about specific aspects of their experiences.  
 When asked for their level of agreement with the statement “I am confident in my ability 
to identify drug related problems when I perform SMAP medication assessments”, 172 of the 
195 respondents (88.2%) agreed or strongly agreed (Figure 15).  
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Figure 15: The number of respondents who indicated their level of agreement with the statement “I am confident in 
my ability to identify drug related problems when I perform SMAP medication assessments”. Total number of 
responses = 195. 
 
 Pharmacists were also asked to respond to the statement “Sometimes I have trouble 
identifying drug related problems when completing a SMAP assessment because I do not have 
enough information about the patient’s medical history”. One hundred thirty-one of the 195 
respondents (67.2%) agreed or strongly agreed (Figure 16).   
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Figure 16: The number of respondents who indicated their level of agreement with the statement “Sometimes I have 
trouble identifying drug related problems when completing a SMAP assessment because I do not have enough 
information about the patient’s medical history”. Total number of responses = 195. 
 
 When asked, “When you are completing a SMAP assessment, how often do you contact 
the physician to request additional information from the patient’s chart?”, only three of the 195 
respondents (1.5%) indicated that they “always” do this (Figure 17). The majority of respondents 
(n=112/195, 57.4%) indicated that they “rarely” (n=87/195, 44.6%) or “never” (n=25/195, 
12.8%) request additional information from the patient’s chart (Figure 17). 
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Figure 17: The number of respondents who indicated how often they contact the physician to request additional 
information from the patient’s chart when completing a SMAP assessment. Total number of responses = 195. 
 
 Following a SMAP assessment and the discovery of potential drug related problems, the 
issues need to be brought to the attention of the patient and/or physician.  The majority of 
pharmacists (96.4%) who responded to the survey agreed that they were comfortable discussing 
their recommendations with patients (Figure 18). 
  
Figure 18: The number of respondents who indicated their level of agreement with the statement “When completing 
a SMAP assessment I feel comfortable discussing my recommendations with patients”. Total number of responses = 
195. 
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Respondents also indicated that patients often agreed with the recommendations that 
were made during the SMAPs. When responding to the question, “How often do patients agree 
with the recommendations that you make when completing a SMAP assessment?”, 150 of the 
195 respondents (76.9%) indicated that patients always or almost always agree with the 
pharmacist’s recommendations (Figure 19).   
  
Figure 19: The number of respondents who indicated how often patients agree with the recommendations that they 
make when completing a SMAP assessment. Total number of responses = 195. 
 
 It is expected that a program like the SMAP would involve collaboration between 
pharmacists and physicians to make appropriate changes to their patient’s medication therapy. 
All respondents, regardless of whether they had completed a SMAP assessment or not, were 
asked to indicate their level of agreement with the statement, “The SMAP encourages 
collaboration between pharmacists and physicians”. A substantial portion, 40, of 153 respondents 
(19.0%) indicated that they were not sure if the SMAP encouraged collaboration between 
physicians and pharmacists and 18 (8.5%) disagreed or strongly disagreed (Figure 20). 
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Figure 20: The number of respondents who indicated their level of agreement with the statement “The SMAP 
encourages collaboration between pharmacists and physicians”. Total number of responses = 211. 
 
In response to the statement, “When completing a SMAP assessment I feel comfortable 
making recommendations to physicians”, the majority, 156, of the 191 respondents (81.7%) 
agreed or strongly agreed (Figure 21).   
  
Figure 21: The number of respondents who indicated their level of agreement with the statement “When completing 
a SMAP assessment I feel comfortable making recommendations to physicians”. Total number of responses = 191. 
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One hundred and one of 192 respondents (52.6%) indicated that physicians “sometimes” 
accept their recommendations when they are completing a SMAP assessment and 63 (32.8%) 
indicated that physicians “almost always” accept their recommendations (Figure 22).  
  
Figure 22: The number of respondents who indicated how often their recommendations are accepted by physicians 
when completing SMAP assessments. Total number of responses = 192. 
 
 Pharmacists have multiple methods to communicate with physicians. The most popular 
method of communication with physicians regarding SMAP assessments amongst respondents 
was via fax, with 182 of the 193 respondents (94.3%) indicating that they typically use this 
method of communication with physicians (Figure 23). Nine respondents indicated that they 
used other methods of communication, including: email, the patient’s electronic medical record 
(EMR), the patient’s chart or a typed assessment hand delivered to the physician’s office (Figure 
23).  
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Figure 23: The number of respondents who indicated that they communicate with physicians regarding SMAP 
assessments via the options listed: fax, phone, in person or other. Respondents could choose multiple response 
options. Total number of respondents = 193. 
 
 A SMAP assessment provides pharmacists an opportunity to help patient properly use 
complicated medication related devices. Respondents were asked, “During a SMAP assessment, 
how often do you have patients who use devices (e.g., inhalers, eye drops, etc.) demonstrate their 
technique?”.  Only 50 of the 187 respondents (26.7%) reported that they “always” or “almost 
always” have patients demonstrate device techniques during a SMAP assessment (Figure 24).  
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Figure 24: The number of respondents who indicated how often they have patients who use devices demonstrate 
their technique during a SMAP assessment. Total number of responses = 187. 
 
 A SMAP assessment also provides an opportunity for the pharmacist to assess the cost-
effectiveness of the medications that the patient is taking and consider lower cost alternatives. 
Respondents were asked, “During a SMAP assessment, how often do you personally assess 
whether patients are on the most cost-effective medications?”. Only 82 of the 188 respondents 
(43.6%) claimed that they “always” or “almost always” do this (Figure 25).  
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Figure 25: The number of respondents who indicated how often they assess whether patients are on the most cost-
effective medications during a SMAP assessment. Total number of responses = 188. 
 
 As part of a complete SMAP medication assessment, pharmacists are required by the 
Ministry of Health to view the patient information available from the Pharmaceutical 
Information Program (PIP), which is a web-based database of prescription medications dispensed 
in any pharmacy across the province, for all patients who receive an SMAP assessment. 
Pharmacists were asked, “How often do you access and view information from the PIP Viewer 
when completing a SMAP assessment?”.  Of the 187 respondents who answered this question, 
only 134 (71.7%) indicated that they “always” access and view information from the PIP Viewer 
to complete a SMAP assessment (Figure 26).   
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Figure 26: The number of respondents who indicated how often they access and view information from the PIP 
Viewer when completing a SMAP assessment. Total number of responses = 187. 
 
 Along with accessing the PIP, pharmacists have another resource available, the electronic 
health record (eHR) Viewer. As it was expected that some pharmacies and pharmacists have not 
completed the appropriate paperwork and training to access the eHR Viewer, all respondents (not 
just those who indicated that they had completed at least one SMAP) were asked, “Do you have 
access to the eHR Viewer in your pharmacy?” (Figure 27).  
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Figure 27: The number of respondents who indicated whether or not they had access to the eHR Viewer in the 
pharmacy where they work. Total number of responses = 201. 
 
Pharmacists who indicated that they had completed at least one SMAP assessment and 
also indicated that they have access to the eHR Viewer were then asked, “How often do you use 
information from the eHR Viewer when completing a SMAP assessment?”.  Ninety-six of the 
161 respondents (59.6%) indicated that they “always” use information from the eHR Viewer 
when completing SMAP assessments (Figure 28).  
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Figure 28: The number of respondents who indicated how often they use information from the eHR Viewer when 
completing a SMAP assessment. Total number of responses = 161. 
 
The 26 respondents who had indicated that they did not have access to the eHR Viewer 
were asked to answer the additional question, “Why do you not have access to the eHR Viewer?” 
(Figure 29). Thirteen respondents indicated “other” and the main reasons pharmacists stated for 
not having access to the eHR Viewer were technical difficulties with the viewer working on their 
dispensary computers, waiting for approval from their “head office”, or having submitted an 
application to eHealth Saskatchewan for access and currently waiting on approval (Figure 29). 
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Figure 29: The number of respondents who indicated why they did not have access to the eHR Viewer in the 
pharmacy where they work. Total number of responses = 26. 
 
6.6 Pharmacists’ Attitudes towards the SMAP 
 Respondents were also asked questions regarding their attitudes towards the SMAP. All 
pharmacists, regardless of whether they have provided the SMAP service or not, were asked, 
“Do you think that providing medication assessments through the SMAP is good use of 
pharmacists’ skills?”.  The majority, 185, of the 203 respondents (91.1%) responded positively 
(Figure 30).  
13 (50.0%) 
2 (7.7%) 
11 (42.3%) 
0	 2	 4	 6	 8	 10	 12	 14	
Other,	please	specify	
The	pharmacy	I	work	in	has	signed	up	for	access,	but	I	have	not.	
The	pharmacy	I	work	in	has	not	signed	up	for	access.	
Why	do	you	not	have	access	to	the	eHR	Viewer?	
 59 
  
Figure 30: The number of respondents who indicated whether or not they think that providing medication 
assessments through the SMAP is a good use of pharmacists’ skills. Total number of responses = 203. 
 
 Respondents, regardless of their experience with the SMAP, were also asked, “Do you 
think that the pharmacy profession in Saskatchewan should focus more on services other than the 
SMAP?”.  There was not as much agreement among respondents when it came to this question 
(Figure 31).  
  
Figure 31: The number of respondents who indicated whether or not they think that the pharmacy profession in 
Saskatchewan should focus more on services other than the SMAP. Total number of responses = 203. 
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 Pharmacists who indicated that they had completed at least one SMAP were asked to 
respond to the statement, “I enjoy performing SMAP assessments”.  The majority of the 188 
respondents, 159 (84.6%), indicated that they enjoyed performing SMAP assessments (Figure 
32).   
  
Figure 32: The number of respondents who indicated their level of agreement with the statement “I enjoy 
performing SMAP assessments”. Total number of responses = 188. 
 
6.7 Barriers to Providing SMAP Medication Assessments 
 A list of potential barriers to providing SMAP assessments was developed (see Methods 
section for details). Respondents were asked to select all the barriers from the list of potential 
options that they feel make it difficult for them to provide SMAP services (Figure 33).  The 
barriers that over half of the 199 respondents selected included: lack of time (n=144/199, 
72.4%); many patients who need the service are not eligible (e.g., age <65, NIHB) (n=130/199, 
65.3%); difficulty in having patients come to the pharmacy due to their reduced mobility  
(n=125/199, 62.8%); lack of patient interest in participating in the program (n=117/199, 58.8%); 
and poor patient awareness of the program (n=108/199, 54.3%) (Figure 33).  
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 Figure 33: The number of respondents who indicated that a barrier from the list is a barrier that makes it difficult for 
them personally to provide SMAP medication assessments. Total number of respondents = 199. 
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 A second question, using the same list of barriers, asked pharmacists to select only the 
top three barriers that make it difficult for them to provide the service (Figure 34). There was 
only one barrier that over half of the 199 respondents selected, which was ‘lack of time’ 
(n=112/199, 56.3%) (Figure 34).   
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 Figure 34: The number of respondents who indicated that a barrier from the list is one of the top three (3) barriers 
that make it difficult for them personally to provide SMAP medication assessments. Total number of respondents = 
199. 
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Interruptions	during	patient	interviews	Lack	of	a	private	consultation	area	in	my	pharmacy	
I	am	not	conUident	in	my	ability	to	perform	a	medication	assessment	
I	frequently	forget	to	offer	service	to	patients	who	are	eligible	
Inadequate	technician/assistant	stafUing	in	my	pharmacy	
Inadequate	remuneration	from	the	Ministry	for	the	program	
Extensive	documentation	requirements	
Unhelpful/complicated	Ministry	documentation	templates	and	forms	
Lack	of	cooperation	with	physicians	Poor	patient	awareness	of	the	program	
Inadequate	access	to	patient's	medical	records	Inadequate	pharmacist	stafUing	in	my	pharmacy	
Lack	of	patient	interest	in	participating	in	the	program	
Many	patients	who	need	the	service	are	not	eligible	(e.g.,	age	<65,	NIHB)	
DifUiculty	in	having	patients	come	to	the	pharmacy	due	to	their	reduced	mobility	or	other	medical	conditions	
Lack	of	time	
From	the	list	provided	below,	please	indicate	the	top	three	(3)	barriers	that	
make	it	difDicult	for	you	personally	to	provide	SMAP	medication	assessments.		
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6.8 Facilitators to Providing SMAP Medication Assessments 
 A list of potential facilitators to providing SMAP assessments was also developed from 
the literature. 13,28,36-39Respondents were asked to select the top three facilitators that help them to 
provide SMAP medication assessments. The facilitators that the 198 respondents chose most 
often included: good teamwork within my pharmacy (n=87/198, 43.9%); support from my 
employer/manager (n=76/198, 38.4%); and, my personal belief that medication assessments are 
important to improve the care of my patients (n=75/198, 37.9%) (Figure 35). 
 65 
 Figure 35: The number of respondents who indicated that a facilitator from the list is one of the top three (3) 
facilitators currently helping them to provide SMAP medication assessments that fulfill the stated purposes of the 
SMAP. Total number of respondents = 198. 
 
 
 
2 (1.0%) 
2 (1.0%) 
5 (2.5%) 
11 (5.6%) 
23 (11.6%) 
35 (17.7%) 
42	(21.2%)	
48	(24.2%)	
56 (28.3%) 
59 (29.8%) 
66 (33.3%) 
75 (37.9%) 
76 (38.4%) 
87 (43.9%) 
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Strong	patient	awareness	of	the	program	
Strong	physician	support	of	the	program	
Effectively	utilizing	technician's	role	to	support	me	in	providing	medication	assessments	
Strong	communication	with	physicians	
Standardized	forms	and	documentation	templates	from	the	Ministry	
Strong	communication	with	patients	
Adequate	pharmacist	stafUing	in	my	pharmacy	
Having	adequate	skills	and	knowledge	to	provide	medication	assessments	
My	personal	interest/passion	in	providing	medication	assessments	
Offering	reviews	on	an	"appointment	only"	basis	
Availability	of	a	private	counselling	area	in	my	pharmacy	
My	personal	belief	that	medication	assessments	are	important	to	improve	the	care	of	my	patients	
Support	from	my	employer/manager	
Good	teamwork	within	my	pharmacy	
From	the	list	provided	below,	please	indicate	the	top	three	(3)	facilitators	
currently	helping	you	to	provide	medication	assessments	that	fulDill	the	stated	
purposes	of	the	SMAP.	
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6.9 Secondary Analysis: Comparisons of the Data to find Relationships  
6.9.1 Question comparisons: One-way Analysis of Variance (ANOVA) 
Seven comparisons were made in the secondary analysis using a One-way Analysis of 
Variance (ANOVA) in an effort to determine if differences exist between the data. A statistically 
significant difference (p < 0.05) was found with two of these comparisons (Table 3). The number 
of SMAP assessments completed in a typical month and respondent’s level of agreement with 
the two statements, “I enjoy performing SMAP assessments” (F(2,185) = 6.489, p = 0.002) and, 
“When completing a SMAP assessment I feel comfortable making recommendations to 
physicians” (F(2,188) = 4.862, p = 0.009), were both found to be statistically significant.  
Table 3: Question comparisons – One-way Analysis of Variance (ANOVA) 
Comparison Questions p-value 
Indicate the number of SMAP 
medication assessments that you 
personally complete in a typical 
month. 
(0, 1-5, 6-21+) 
I enjoy performing SMAP assessments. 0.002 
Sometimes I have trouble identifying drug related problems 
when completing a SMAP assessment because I do not have 
enough information about the patient’s medical history. 
0.823 
When completing a SMAP assessment I feel comfortable 
making recommendations to physicians. 
0.009 
How many years have you been a 
licensed pharmacist? 
(1 year or less, 2-5 years, 6-10 
years, 11-20 years, 21-30 years, 
more than 30 years) 
I am confident in my ability to identify drug related 
problems when I perform SMAP medication assessments. 
0.854 
When you are completing a SMAP assessment, how often 
do you contact the physician to request additional 
information from the patient’s chart? 
0.435 
When completing a SMAP assessment I feel comfortable 
making recommendations to physicians. 
0.339 
What is the population of the 
community where your pharmacy 
is located? 
(Rural, Small City, Large City) 
The SMAP encourages collaboration between pharmacists 
and physicians. 
0.662 
Table 3: The results of the question comparisons using One-way Analysis of Variance (ANOVA). Significant results 
are shown in bold. 
 
6.9.2 Question Comparisons: Tukey Post Hoc Analysis 
 For the two comparisons indicated above that were shown to be statistically significant, 
Tukey post hoc analysis was done to compare the groups in an attempt to identify the source of 
the specific significant relationships (Table 4).  
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Table 4: Post Hoc Analysis – Tukey Test 
 N (%) Mean  p-value 
Indicate the number of SMAP 
medication assessments that you 
personally complete in a typical 
month. 
I enjoy performing SMAP assessments. 
Strongly agree = 1 
Agree = 2 
Not sure = 3 
Disagree = 4 
Strongly disagree = 5 
0 vs  
1 to 5 
19 (10.1%) 
149 (79.6%) 
2.32 
2.00 
0.263 
0 vs  
6 to 21+ 
19 (10.1%) 
20 (10.6%) 
2.32 
1.40 
0.002 
1 to 5 vs  
6 to 21+ 
149 (79.6%) 
20 (10.6%) 
2.00 
1.40 
0.008 
Indicate the number of SMAP 
assessments that you personally 
complete in a typical month. 
When completing a SMAP assessment I feel comfortable 
making recommendations to physicians. 
Strongly agree = 1 
Agree = 2 
Not sure = 3 
Disagree = 4 
Strongly disagree = 5 
0 vs  
1 to 5 
19 (9.9%) 
151 (79.1%) 
2.53 
2.09 
0.027 
0 vs  
6 to 21+ 
19 (9.9%) 
21 (11.0%) 
2.53 
1.86 
0.008 
1 to 5 vs  
6 to 21+ 
151 (79.1%) 
21 (11.0%) 
2.09 
1.86 
0.337 
Table 4: The results of the post hoc analysis using the Tukey test. Significant results are shown in bold.  
 
For the comparison between “Indicate the number of SMAP medication assessments that 
you personally complete in a typical month” and “I enjoy performing SMAP assessments”, post 
hoc analysis showed two significant relationships with significance set at p = 0.05. Respondents 
had statistically significantly less agreement with the statement, “I enjoy performing SMAP 
assessments” if they indicated that they complete zero (2.32 ± 0.885, p = 0.002) and 1 to 5 (2.00 
± 0.854, p = 0.008) SMAP assessments in a typical month than if they indicated they complete 6 
to 21+ SMAP assessments (1.40 ± 0.503) (Table 4). 
For the comparison between “Indicate the number of SMAP medication assessments that 
you personally complete in a typical month” and “When completing a SMAP assessment I feel 
comfortable making recommendations to physicians”, post hoc analysis also showed two 
significant relationships with significance set at p = 0.05. Respondents had statistically 
significantly more agreement with the statement, “When completing a SMAP assessment I feel 
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comfortable making recommendations to physicians” if they indicated that they complete 1 to 5 
(2.09 ± 0.692, p = 0.027) and 6 to 21+ (1.86 ± 0.727, p = 0.008) SMAP assessments in a typical 
month than if they indicated they complete zero SMAP assessments (2.53 ± 0.697) (Table 4). 
 
6.9.3 Barriers/Facilitators vs. Number of SMAP Assessments Performed: Pearson Chi-Squared 
 To determine if there was a relationship between whether or not respondents selected the 
most commonly indicated barriers and facilitators and the number of SMAP assessments that 
they completed in a typical month, this data was organized into cross tabulations and Pearson’s 
chi-squared was used to test for significance.  
Part B, Question 2, “From the list provided below, please indicate the top three (3) 
barriers that make it difficult for you personally to provide SMAP medication assessments”, 
resulted in four popular answers including: lack of time (n=112/199, 56.3%); difficulty in having 
patients come to the pharmacy due to their reduced mobility or other medical conditions 
(n=69/199, 34.7%); many patients who need the service are not eligible (e.g., age <65, NIHB) 
(n=63/199, 31.7%); and lack of patient interest in the program (n=52/199, 26.1%). These four 
barriers were compared to Question 2, “Indicate the number of SMAP medication assessments 
that you personally complete in a typical month”, and no statistically significant results were 
found with significance set at p = 0.05 (Table 5). 
Table 5: Number of SMAP assessments performed vs. Barriers – Pearson Chi-squared 
 Barrier Selected/ 
Not selected 
N p-value 
Indicate the 
number of 
SMAP 
medication 
assessments 
that you 
personally 
complete in 
a typical 
month 
Lack of time 
Not selected 
Selected 
Total 
84 (45.4%) 
101 (54.6%) 
185 
0.204 
Difficulty in having 
patients come to the 
pharmacy due to their 
reduced mobility or other 
medical problems 
Not selected 
Selected 
Total 
120 (64.9%) 
65 (35.1%) 
185 
0.200 
Many patients who need 
the service are not eligible 
(e.g., age <65, NIHB) 
Not selected 
Selected 
Total 
125 (67.6%) 
60 (32.4%) 
185 
0.167 
Lack of patient interest in 
participating in the 
program 
Not selected 
Selected 
Total 
135 (73.0%) 
50 (27.0%) 
185 
0.950 
Table 5: The results of the comparison between the number of SMAP assessments performed by a pharmacist and 
whether or not the pharmacist had selected the top barriers. No significant results were found. 
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 Part B, Question 4, “From the list provided below, please indicate the top three (3) 
facilitators that currently help you to provide medication assessments that fulfill the stated 
purposes of the SMAP”, resulted in six popular answers including: good team work within my 
pharmacy (n=87/198, 43.9%); support from my employer/manager (n=76/198, 38.4%); my 
personal belief that medication assessments are important to improve the care of my patients 
(n=75/198, 37.9%); availability of a private counseling area in my pharmacy (n=66/198, 33.3%); 
offering reviews on an “appointment only” basis (n=59/198, 29.8%); and my personal 
interest/passion in providing medication assessments (n=56/198, 28.3%). These six facilitators 
were compared to Question 2, “Indicate the number of SMAP medication assessments that you 
personally complete in a typical month”, using Pearson Chi-squared test and no statistically 
significant results were found with significance set at p = 0.05 (Table 6).  
Table 6: Number of SMAP assessments performed vs. Facilitators – Pearson Chi-
Squared 
 Facilitator Selected/ 
Not selected 
N p-value 
Indicate the 
number of 
SMAP 
medication 
assessments 
that you 
personally 
complete in 
a typical 
month 
Good teamwork within my 
pharmacy 
Not selected 
Selected 
Total 
101 (54.3%) 
85 (45.7%) 
186 
0.194 
Support from my employer/ 
manager 
Not selected 
Selected 
Total 
114 (61.3%) 
72 (38.7%) 
186 
0.445 
My personal belief that 
medication assessments are 
important to improve the care 
of my patients 
Not selected 
Selected 
Total 
114 (61.3%) 
72 (38.7%) 
186 
0.144 
Availability of a private 
counseling area in my 
pharmacy 
Not selected 
Selected 
Total 
124 (66.7%) 
62 (33.3%) 
186 
0.090 
Offering reviews on an 
“appointment only” basis 
Not selected 
Selected 
Total 
130 (69.9%) 
56 (30.1%) 
186 
0.057 
My personal interest/passion 
in providing medication 
assessments 
Not selected 
Selected 
Total 
133 (71.5%) 
53 (28.5%) 
186 
0.122 
Table 6: The results of the comparison between the number of SMAP assessments performed by a pharmacist and 
whether or not the pharmacist had selected the top facilitators. No significant results were found. 
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6.10 Non-response Bias 
 A comparison of responses from early and late respondents to the closed-ended questions 
was done to assess for potential non-response bias. With significance set at p=0.05, there were no 
significant differences between the responses given by early and late respondents. 
 The second method used to assess for non-response bias was a comparison of the 
demographic characteristics of the respondents to the demographic characteristics of the entire 
population of pharmacists in Saskatchewan. The demographic characteristics between the 
respondents to this survey and the population of Saskatchewan pharmacists in 2014 are similarly 
distributed as seen in Table 7 below. 
Table 7: Demographic Comparison of Respondents to the Population of Saskatchewan 
Pharmacists in 2014 
Demographics 
(questionnaire) 
Respondents Demographics 
(CIHI 2014) 
Saskatchewan 
pharmacists 
Position: 
Pharmacy owner 
Pharmacy manager 
Staff pharmacist 
Relief/casual pharmacist 
 
26 (13.1%) 
36 (18.1%) 
128 (64.3%) 
9 (4.5%) 
Position: 
Pharmacy owner/manager 
Staff pharmacist 
Other 
Missing values 
 
355 (25.1%) 
955 (67.5%) 
103 (7.3%) 
2 (0.1%) 
Hours worked in a 
community pharmacy setting 
in a typical week: 
Less than 10 hours 
10 – 20 hours 
21 – 30 hours 
31 – 40 hours 
More than 40 hours 
 
 
 
8 (4.0%) 
11 (5.5%) 
22 (11.0%) 
115 (57.5%) 
44 (22.0%)   
Estimated weekly practice 
hours: 
 
0 – 14 
15 – 29 
30 – 39 
40 + 
Missing values 
 
 
 
87 (6.1%) 
237 (16.7%) 
475 (33.6%) 
612 (43.3%) 
4 (0.3%) 
Gender: 
Male 
Female 
Prefer not to answer 
 
44 (22.0%) 
152 (76.0%) 
4 (2.0%) 
Sex: 
Male 
Female 
Missing values 
 
470 (33.2%) 
945 (66.8%) 
0 
Years as a licensed 
pharmacist: 
0 – 10 
11 – 20 
21 – 30 
31 + 
 
 
93 (47.0%) 
48 (24.2%) 
36 (18.2%) 
21 (10.6%) 
Years since graduation: 
 
0 – 10 
11 – 20 
21 – 30 
31 + 
Missing values 
 
 
563 (39.8%) 
325 (23.0%) 
246 (17.4%) 
276 (19.5%) 
5 (0.4%) 
Location of graduation: 
International pharmacy 
graduate 
Canadian pharmacy graduate 
 
8 (4.0%) 
 
191 (96.0%) 
Location of graduation: 
International  
Canada 
Missing values 
 
59 (4.2%) 
1355 (95.8%) 
1 (0.1%) 
Table 7: The results of the demographic comparison of the respondents to the population of Saskatchewan 
Pharmacists in 2014.  
 
6.11 Themes from Open-ended / Free-text Questions 
There were nine open-ended/free-text questions included in the questionnaire, mostly 
asking respondents to expand on Likert scale answers or to provide additional comments or 
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recommendations (Appendix C). Each open-ended question was intended to explore a particular 
aspect of the SMAP and pharmacists’ attitudes; however, when the data from the open-ended 
questions were analyzed it became evident that many respondents did not keep to the topic of the 
questions. For example in Part A, Section 1, question #16, which asked about potential changes 
to make communication with physicians more effective, one respondent wrote about decreasing 
the eligibility age limit for the SMAP to 60 years. Consequently, after analyzing the data from 
each question separately (to identify any common themes related to each individual question), 
the data from the nine open-ended questions were combined into one dataset and analyzed as a 
whole (to identify any common themes related to respondent’s unsolicited commentary). 
Following the analysis, an external audit was done and the auditor agreed that the resulting 
themes aligned with the original responses to the survey questions. 
 
6.11.1 Overall Themes from Combined Dataset 
The overall themes that emerged from the combined data from all nine open-ended 
questions included: (1) lack of collaboration and communication between physicians and 
pharmacists; (2) lack of patient information and medical history to complete an assessment; (3) 
mandatory SMAP documentation forms are repetitive and require duplication of information; (4) 
workplace environment is not supportive of delivering high quality SMAPs; (5) pressure on 
pharmacists to complete a high volume of medication assessments (i.e., “quotas”); (6) eligibility 
criteria needs to be expanded; (7) concerns regarding the consistency and quality of the 
medication assessments; (8) lack of physician and patient awareness and understanding of the 
SMAP; and (9) difficulty assessing complex patients. 
  
Theme 1: Lack of collaboration and communication between physicians and pharmacists 
A lack of collaboration and communication between physicians and pharmacists was a 
common theme in many responses. Pharmacists believed that communication with physicians 
about the SMAP was poor and as a consequence collaboration between physicians and 
pharmacists to resolve the drug therapy problems identified during the SMAP often did not take 
place. One respondent pointed out: 
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The real issue is that there may be no significant impact with doing med assessments if 
physicians and pharmacists do not actually work together to resolve or prevent drug 
related problems. (respondent 220, staff pharmacist) 
 
Respondents believed that the lack of communication and collaboration was due to a lack 
of effort or interest on the part of the physician:  
 
I don’t know what else I can do from my end to make communication more effective. I 
believe that the recommendations I make would benefit my patients and they are based on 
best available evidence, but quite often I get the impression that the physicians do not 
even read faxed recommendations. (respondent 101, staff pharmacist) 
 
However, respondents also recognized that in order to improve communication and 
collaboration with physicians they must work to develop a relationship with the physicians:  
 
Having a good relationship with the physician/clinic is key, so that is something that is up 
to the pharmacist/pharmacy (respondent 120, staff pharmacist); 
 
I think the most effective solution would be to actually sit down with the doctors we deal 
with most often and see what they think of the program and the most effective means of 
communication (respondent 126, staff pharmacist). 
 
Theme 2: Lack of patient information and medical history to complete an assessment 
Many respondents commented on the lack of patient information and medical history that 
is available to community pharmacists. While respondents praised the availability of the 
electronic Health Record (eHR) Viewer and Pharmaceutical Information Program (PIP) to access 
lab work, immunization histories, and a complete list of prescription medications, they still felt 
that they lacked access to all the information necessary to complete a thorough assessment (e.g., 
specialist physician consultation reports, diagnostic test results).  
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Patients understanding of their medication and background knowledge is a huge barrier. 
Sometimes I will have a patient that literally knows nothing about their medication or 
medical conditions (respondent 28, staff pharmacist). 
 
Some respondents, while recognizing that the eHR Viewer has the potential to be a 
valuable source of information, stated that it was either incomplete or displayed no information 
at all depending on the health region where the patient had lab work done.  
 
EHR viewer does not display the local lab information, therefore unless my patient gets 
blood work elsewhere I am unable to see any of their blood work (respondent 109, staff 
pharmacist). 
 
 Respondents felt it was a barrier to not have direct access to the patients’ medical chart 
and they commented that requesting this information from the patient’s family physician was 
difficult and time consuming.  
 
I would never even consider contacting the physician to get more info from the patient’s 
chart due to time constraints (respondent 224, staff pharmacist). 
 
Theme 3: Mandatory SMAP documentation forms are repetitive and require duplication 
of information 
Respondents identified the mandatory SMAP documentation forms as a source of 
frustration. The forms were said to be repetitive and required duplication of information, which 
unnecessarily increased the time required for documentation. Respondents provided several 
suggestions to improve the forms, such as: 
 
Condense the documentation. I feel like I repeat the same info on multiple forms 
(respondent 41, staff pharmacist); 
 
I’m not sure about improvement but streamline the forms, and cut out the redundancy 
(respondent 67, staff pharmacist); 
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I am not a fan of the current forms. They do not have space for proper info to be written 
and seem unorganized in flow for asking questions (respondent 155, pharmacy owner). 
 
Theme 4: Workplace environment is not supportive of delivering high quality SMAPs 
The community pharmacy workplace, in general, was identified as an environment that is 
not supportive of delivering high quality SMAPs.  
 
The retail pharmacy is NOT the place for such a process to occur. Pharmacists need to 
be employed and staffed in physicians’ clinics – and meet with patients in this 
environment; with access to the patient chart, with access to the prescribing physicians to 
allow for open discussion. (respondent 75, staff pharmacist) 
 
One pharmacist shed light on her typical workday in a community pharmacy setting: 
 
I usually work 8hrs standing the entire time going nonstop and have to rush away to use 
the washroom and eat while standing at the computer. When you get home exhausted the 
last thing you think about is how to perform more SMAPs (respondent 221, staff 
pharmacist). 
 
Respondents referred to a lack of staffing, workflow issues, poor access to resources and 
technology, and a lack of time as reasons why the community pharmacy setting is not the ideal 
place to perform medication assessments. Some respondents believed that a service such as the 
SMAP is too time intensive for the community practice setting.  
 
 I find there isn’t enough time to offer, prepare for and then conduct the interview. . . . 
[T]here just isn’t any spare uninterrupted time to work on the assessments (respondent 
39, pharmacy manager); 
 
 Lack of time is by far our biggest barrier and we actually do have adequate pharmacist 
staffing but we have to improve our workflow and organize our time more efficiently. We 
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go through very busy periods and get behind on other things so we don’t book as many 
SMAP’s and they just start to fall by the wayside. (respondent 126, staff pharmacist) 
 
Theme 5: Pressure on pharmacists to complete a high volume of medication assessments 
(i.e., “quotas”) 
Respondents felt that many pharmacists were being put under pressure by management to 
complete a high volume of medication assessments.  
 
Corporate owners want quotas and we must do these at the most inopportune times with 
little prep time and being rushed to complete them (respondent 19, staff pharmacist). 
 
Many respondents used the term “quotas” to describe the situation and suspected that 
pharmacies could be abusing the program. One respondent felt that the pressure of perceived 
quotas did not make them feel like a healthcare worker: 
 
A lot of employers expect a certain number of SMAPs to be done per specific time period. 
Sounds like quotas…. doesn’t exactly make one feel like a “healthcare worker” to me 
(respondent 162, relief/casual pharmacist). 
 
Theme 6: Eligibility criteria needs to be expanded 
The eligibility criteria for SMAP assessments was another focus for respondents, who felt 
that it should be expanded. Respondents specifically suggested that the program be expanded to 
include patients who are less than 65 years old, those who have chronic conditions, and 
individuals who are covered by Health Canada’s Non-insured Health Benefits (NIHB) Drug Plan 
(which insures First Nations and Inuit people). It was also suggested that the requirement for a 
face-to-face interview be eliminated to allow assessments to be performed over the phone.  
 
The annual review is sometimes difficult to perform because of mobility changes or 
decline in cognitive function doesn’t allow us to perform a face to face interview but the 
compliance packaging is still important to the patient but no longer billable (respondent 
214, staff pharmacist). 
 76 
 
Theme 7: Concerns regarding the consistency and quality of the medication assessments  
There was concern among respondents regarding the consistency and quality of the 
medication assessments provided across pharmacies and by other pharmacists. Respondents 
believed that poor quality assessments performed by other pharmacists affect how physicians and 
patients perceived the SMAP and the pharmacy profession.  
 
Some pharmacies are encouraging SMAPs to be done in 10-15 minutes. We have come 
across patients that don’t even know they had a SMAP, it was done that quickly. That 
really upsets me as somebody who takes time to do SMAPs with patients, out of respect to 
my profession and them. It’s more than about finding drug therapy problems. It’s about 
giving the patient a chance to be heard and have a say in their health. It’s about learning 
more about them and their values. With the lack of consistency with SMAPs I am 
concerned how doctors perceive the SMAP. If a doctor wants a patient to have a 
medication assessment, will it affect our profession if some are given in 15 minutes and 
some in 60? The language needs to change. If it’s going to be of a lower quality it 
shouldn’t be called a medication assessment. (respondent 129, staff pharmacist) 
 
Theme 8: Lack of physician and patient awareness and understanding of the SMAP 
Respondents felt that there was a lack of physician and patient awareness and 
understanding of the purpose and the benefits of the SMAP. Respondents believed that 
physicians and patients would be more receptive of the SMAP if they had a better understanding 
of the program and what it was meant to accomplish.  
 
Some patients associate medication assessments with age and a decrease in individual 
function. They assume that it’s something you need when you don’t understand your 
medications any more. It has been a challenge to explain that these can benefit all people 
at all stages of life, and that it can also be a maintenance check to learn more about 
medications. (respondent 129, staff pharmacist) 
 
Theme 9: Difficulty assessing complex patients 
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Some respondents felt that it was difficult to assess very complex patients. There were a 
variety of reasons cited for this including: inadequate compensation, unsure of knowledge and 
skills, lack of time, and a lack of awareness of referral options.  
 
SMAP does not pay enough for challenging patients (respondent 193, staff pharmacist),  
 
It takes longer than one hour to go through the required forms and then go through what 
is important to the patient, then to fill out the forms, send them to their family doctor and 
follow up with both parties. This could take two or three hours for a complicated patient 
and community pharmacy does not in most cases allow for this. (respondent 43, 
pharmacy manager) 
 
6.11.2 Themes from Individual Questions 
The first open-ended question (Part A, Section 1, Question #9, Appendix C) asked 
respondents, “If you answered “disagree” or “strongly disagree” for the previous question, please 
explain why you are not comfortable making recommendations to patients”. The previous 
question (Question #8, Appendix C) was, “When completing a SMAP assessment I feel 
comfortable discussing my recommendations with patients”. Only five respondents (n=5/195, 
2.6%) answered this open-ended question and these responses did not elicit adequate data to 
identify specific themes related to this question; however, the responses contributed to the 
previous list of overall themes. 
The second open-ended question (Part A, Section 1, Question #13, Appendix C) asked 
respondents, “If you answered “disagree” or “strongly disagree” for the previous question, please 
explain why you are not comfortable making recommendations to physicians”. The previous 
question (Question #12, Appendix C) was, “When completing a SMAP assessment I feel 
comfortable making recommendation to physicians”.  Eighteen of the 191 respondents (9.4%) 
answered this open-ended question and the responses did not elicit adequate data to identify 
specific themes related to this question; however, the responses contributed to the previously 
listed overall themes. 
As it was suspected that a lack of communication with physicians would be a barrier to 
completing a high quality SMAP, respondents were asked in the third open-ended question (Part 
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A, Section 1, Question #16, Appendix C), “What changes (if any) would you make to the SMAP 
to make communication with physicians more effective?”. There were 112 responses to this 
question (n=112/228, 49.1%), which contributed to four of the previously listed overall themes, 
including: (1) lack of collaboration and communication between physicians and pharmacists; (3) 
mandatory SMAP documentation forms are repetitive and require duplication of information; (7) 
concerns regarding the consistency and quality of the medication assessments; and (8) lack of 
physician and patient awareness and understanding of the SMAP.  
In Part A, Section 2, Question #1 of the questionnaire (Appendix C), respondents were 
asked, “Do you think providing medication assessments through the SMAP is a valuable use of 
pharmacist’s skills?”. To explore the reasoning behind respondents who indicated “no”, the 
respondents were asked in the fourth open-ended question (Part A, Section 2, Question 2, 
Appendix C), “If you answered “NO”, please explain”. Eleven respondents chose to answer the 
question (n=11/203, 5.4%), which did not result in enough data to identify specific themes 
related to this question. The responses did contribute to the previously listed overall themes.  
In Part A, Section 2, Question #4, respondents were asked, “Do you think the pharmacy 
profession in Saskatchewan should focus more on services other than the SMAP?”. Section 2, 
Question #5, asked respondents, “If you answered “YES”, what other services should 
pharmacists be focusing on?”. There were 54 responses to the open-ended question (n=54/203, 
26.6%).  The services that were recommended by respondents included: providing 
immunizations and other injections, minor ailment prescribing, prescriptive authority, chronic 
disease management (e.g., diabetes, asthma and COPD), and ordering and interpreting laboratory 
tests. One respondent wrote: 
 
I think we need to focus on other services that are available to us as pharmacists such as 
minor ailments, giving influenza vaccines, etc. but I don’t think this should detract from 
our focus on SMAP’s (respondent 126, staff pharmacist). 
 
Respondents also expressed concern for the future of the pharmacy profession: 
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I believe we need to look at building other funding models for pharmacists going forward 
beyond SMAPs to ensure long term viability for our profession (respondent 202, 
unknown); 
 
 As well as focusing on the SMAP, I think we’re going to need more ‘fee for service’ 
opportunities especially with technicians becoming regulated and the inevitable three 
month supply for one dispensing fee coming up (respondent 227, staff pharmacist). 
 
In order to identify additional barriers that were not identified in the literature, Part B, 
Question #3, asked respondents to, “Please share any barriers to providing SMAP assessments 
that you have encountered in your practice that are not included in the previous list”. There were 
47 responses to this question (n=47/228, 20.6%) and most of the barriers that were mentioned in 
the written responses were either already included in the list developed from the literature or 
were specific examples of the barriers already included in the list.  
 The only “new” barrier mentioned in these free-text responses was a concern about the 
variability in the quality of SMAP assessments performed in different pharmacies and by 
different pharmacists (which became one of the overall themes discussed previously). 
 In order to identify additional facilitators that were not already identified in the literature, 
Part B Question #5 asked respondents to, “Please share any facilitators to providing SMAP 
assessments that you have identified in your practice that are not included in the previous list”. 
There were 28 responses to this question (n=28/228, 12.3%). There were three facilitators that 
were frequently mentioned in these responses, which included: (1) pharmacists offering home 
visits to patients unable to make it into the pharmacy for an assessment, (2) a computer system 
which pre-populates the mandatory SMAP forms with some patient information to reduce the 
documentation burden, and (3) access to PIP and eHR Viewer. Other facilitators suggested less 
frequently by respondents included: longevity in the community creating a high level of trust in 
the pharmacist(s), seeking help from a clinical pharmacist to complete assessments, training 
through the CPhA’s ADAPT program that allows pharmacists too feel more prepared to offer 
medication assessments, and word of mouth, from patients who have had an assessment, about 
the benefits of the program.  
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 Part B, Question #6, “Please use the space below to comment on any additional 
suggestion to improve the SMAP”, was the final open-ended question to gather additional 
suggestions from respondents. There were 63 responses to question #6 (n=63/228, 27.6%). These 
responses were used to compile the overall list of themes that were previously discussed.  
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CHAPTER 7 
DISCUSSION 
 
7.1 Do pharmacists believe that the Saskatchewan Medication Assessment Program is 
fulfilling its intended purposes? 
Community pharmacists in Saskatchewan who responded to this survey appear to believe 
that the Saskatchewan Medication Assessment Program (SMAP) is fulfilling most of the 
intended purposes, based on the finding that the majority of respondents agreed or strongly 
agreed to many of the Likert scale survey questions. However, several inconsistencies and 
contradictions are evident when the Likert scale responses are combined with the free-text 
comments. For example, even though the majority of respondents (88.8%) agreed or strongly 
agreed that “assessments provided through the SMAP prevent drug related problems for 
seniors”, the majority of respondents (67.2%) also agreed or strongly agreed that they sometimes 
have trouble identifying drug related problems when completing a SMAP assessment because 
they do not have enough information about the patient’s medical history. It seems unlikely that 
drug related problems are consistently being prevented if over 60% of pharmacists are having 
trouble identifying them. In the responses to the free-text questions, respondents also had 
concerns about the community pharmacy workplace environment not being supportive of 
delivering high quality SMAPs and concerns regarding the consistency and quality of the 
medication assessments provided, which both bring into question the conclusion that the SMAP 
is consistently fulfilling its intended purposes.  
Consequently, based on this combination of positive and negative responses, it is 
questionable whether the respondents consistently and confidently believe that the SMAP is 
meeting its intended purposes.  
   
7.2 Key Barriers and Facilitators to providing the Saskatchewan Medication Assessment 
Program 
The results of this study suggest that a lack of pharmacist time is the most significant 
barrier that respondents feel is interfering with their ability to provide SMAP medication 
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assessments. Respondents selected ‘Lack of time’ most often when asked to select all barriers 
that were relevant (n=144/199, 72.4%) and it was also amongst the top three barriers when 
respondents were asked to prioritize (n=112/199, 56.3%). Respondents also regularly made 
mention of the lack of time issue in their responses to the free-text questions by either simply 
stating that a lack of time was an issue or citing other issues that were related to a lack of time, 
such as time-consuming documentation forms, a work environment not suited to a time-intensive 
medication assessment service, pressure to complete high volumes of assessments in less time, 
and difficulty assessing complex patients partly due to the increased time commitment.  
Two additional barriers that were of significant concern to respondents were: ‘difficulty 
in having patients come to the pharmacy due to their reduced mobility or other medical 
conditions’ and ‘many patients who need the SMAP service are not eligible’. Several suggested 
that program eligibility criteria be expanded to include younger patients and those who are 
federally insured (e.g., First Nations, RCMP) and to allow for phone interviews. 
The facilitators most often selected from the list of facilitators included: ‘good teamwork 
within my pharmacy’ (n=87/198, 43.9%), ‘support from my employer/manager’ (n=76/198, 
38.4%), and ‘my personal belief that medication assessments are important to improve the care 
of my patients’ (n=75/198, 37.9%).  
These barriers and facilitators are similar to those that have been previously identified in 
the literature, suggesting that the experiences of Saskatchewan pharmacists are consistent with 
those in other provinces and countries 13,28,36-39. However, it is disconcerting that these same 
barriers were experienced with this relatively new program in Saskatchewan, despite the fact that 
multiple previous programs have struggled in similar ways. One would hope that a new program 
could have learned the lessons from those who came before them.  
The findings of this study should be useful to the Pharmacy Association of Saskatchewan 
and the Saskatchewan Ministry of Health as they work collaboratively to improve and refine the 
SMAP so that the barriers can be addressed, the facilitators can be shared, and the program can 
achieve its intended purposes. This study should also be useful for other jurisdictions that are 
developing new medication assessment programs, allowing them to proactively incorporate these 
findings into their policies and procedures, in an attempt avoid some of the struggles that have 
been experienced in Saskatchewan.  
 
 83 
7.3 Key strategies pharmacists would like to see implemented to assist them to fulfill the 
purposes of the Saskatchewan Medication Assessment Program (SMAP) 
This study also aimed to identify some strategies that pharmacists would like to see 
implemented to assist them to fulfill the purposes of the SMAP. Some key suggestions that 
emerged were: (1) increased collaboration and improved communication between pharmacists 
and physicians, (2) better access to patient information and medical history, (3) improved 
documentation forms that do not require duplication of information, (4) policies to eliminate 
pressure or “quotas” imposed by employers or corporations, (5) expansion of the eligibility 
criteria and elimination of the requirement for a face-to-face interview, (6) auditing or other 
quality controls to ensure consistency and quality of assessments across pharmacies / 
pharmacists, (7) improved physician and patient awareness about the SMAP, and, (8) options to 
refer complex patients that can not be adequately assessed in the community pharmacy setting.  
These suggestions are clearly linked to the key barriers that emerged from this study and 
therefore seem like reasonable and logical requests that could address many of the barriers and 
potentially lead to improvements of the SMAP. These findings should be useful to the Pharmacy 
Association of Saskatchewan and the Saskatchewan Ministry of Health as they work 
collaboratively to improve and refine the SMAP.  
 
7.4 Findings Consistent with the Current Literature 
Many of the findings in this study are consistent with previous studies of community 
pharmacy led medication assessment programs. For example, pharmacists who responded to the 
questionnaire in this study reported positive perceptions with regard to the value of the SMAP. 
The majority of pharmacists either agreed or strongly agreed that the SMAP was fulfilling its 
intended purposes. This finding is consistent with studies performed in Ontario 28, British 
Colombia 13, and the United Kingdom 37, which all reported positive perceptions by practicing 
pharmacists. Pharmacists responding to a mailed questionnaire or telephone interview about the 
MedsCheck program in Ontario believed that it improved patient health outcomes, adherence, 
and knowledge. 28 They also believed that it allowed pharmacists the opportunity to better 
educate and build relationships with their patients. 28 Pharmacists involved in semi-structured 
focus groups and interviews regarding the program in British Columbia believed that it made 
patients more informed about their medications, increased effectiveness and/or decreased 
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adverse effects of medications, and strengthened the patient-pharmacist relationship. 13 
Pharmacists responding to a mailed questionnaire about a program in the UK believed that 
medication assessments improved their understanding of their patient’s views about medications 
and that the assessments improved patients’ use of medications. 37 
 There were several other similarities between the results of this study and responses from 
pharmacists in other surveys regarding similar medication assessment programs. When 
pharmacists were asked in this study if they thought that providing medication assessments was a 
good use of pharmacist’s skills, 91% agreed. Similarly, 86% of pharmacists responding to a 
survey about a similar service in the United Kingdom agreed that it allowed for better use of 
pharmacists’ professional skills. 37 A survey performed in Qatar, intended to evaluate 
pharmacists’ attitudes about a medication assessment program prior to implementation, found 
that 95.7% of respondents agreed that the program would be an excellent use of pharmacists’ 
skills. 38  
As another example of consistency with previous research, the majority of respondents in 
this study agreed or strongly agreed that they enjoyed performing SMAP assessments. Ontario 
pharmacists responding to a survey about the MedsCheck program indicated that providing 
medication assessments improved their job satisfaction and BC community pharmacists felt that 
medication assessments increased pharmacists’ professional fulfillment. 13,28 As well, findings 
from a systematic review found that pharmacist-led medication assessments resulted in positive 
satisfaction outcomes for both physicians and pharmacists. 6   
 Extensive research has been previously conducted to identify barriers and facilitators to 
community pharmacists providing clinical services such as medication assessments. 13,28,36-39 The 
responses from Saskatchewan pharmacists in this study revealed that they experience similar 
barriers and facilitators to providing SMAP services, compared with pharmacists in other 
provinces and countries who provide similar medication assessment services. For example, in a 
survey of Ontario pharmacists, respondents indicated that the major barriers that they faced when 
completing medication assessments were a lack of time and lack of pharmacist overlap to cover 
the dispensary. 28 Similarly, many Saskatchewan pharmacists responding to this study indicated 
that a ‘lack of time’ and ‘inadequate pharmacist staffing in my pharmacy’ were significant 
barriers that made it difficult for them to provide SMAP medication assessments.  
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Focus groups and interviews with pharmacists from British Columbia found that, much 
like studies in Saskatchewan and Ontario, time-consuming documentation and the financial 
feasibility of offering this type of service in a community pharmacy setting were important 
barriers. 13 Pharmacists in British Columbia had identified an additional barrier that was not 
identified by Ontario pharmacists, which was a negative attitude by physicians towards the 
program. 13 Similarly, respondents in this study regarding the SMAP indicated ‘lack of 
cooperation with physicians’ as a significant barrier.  
In another example of the consistency between the barriers and facilitators identified in 
this study with the previous literature, a survey conducted in the United Kingdom revealed 
similar barriers to those found in this study. 37 Seventy-four percent of pharmacists responding to 
the medicines use review (MUR) survey indicated that a lack of time was a barrier to conducting 
MUR, making it the most selected barrier by both UK and Saskatchewan pharmacists. 37 Like 
pharmacists from Saskatchewan, Ontario and BC, 50% of respondents to the UK questionnaire 
cited the lack of a reasonable financial incentive as a barrier to providing MUR services. 13,28,37 
Similar to Saskatchewan pharmacists indicating a lack of cooperation with physicians and BC 
pharmacists feeling physicians had a negative attitude toward the program, 43% of the 
responding UK pharmacists had doubts about general practitioners’ beliefs that the service was 
valuable. 13,37  
The survey of Ontario pharmacists regarding initial experiences with the MedsCheck 
program was the only research that reported on the facilitators that pharmacists identified to 
providing medication assessments. 28 Ontario pharmacists identified several facilitators that were 
similar to those identified in this study, including: pharmacist overlap, offering reviews on an 
appointment only basis, availability of a private counseling area, good teamwork, and having 
adequate skills and knowledge. 28 
Respondents to the open-ended questions in this study also shared the concerns identified 
by a CBC Marketplace investigation 40 and a recent survey of BC pharmacists 62 that identified 
the community pharmacy was a workplace environment that is not supportive of delivering high 
quality advanced pharmacy services and that pharmacists are often pressured to complete a high 
volume of medication assessments (i.e. “quotas”). 40,62  
It is encouraging that several findings in this study align with findings from others in 
Canada and internationally because it adds to the trustworthiness and credibility of the results. 
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However, the consistency of findings related to program barriers is also somewhat disappointing, 
as one would hope that new programs would be able to avoid the struggles that previous 
programs have experienced. It is impossible to determine from the findings of this study if these 
common barriers are explained by the fact that the developers of the SMAP were not aware of 
the experiences of previous medication assessment programs or if they attempted to proactively 
address the barriers, but were unsuccessful.    
This study provides a useful addition to the existing body of literature on the topic, 
reinforcing and strengthening what is already known. This consistency of findings also 
demonstrates that the challenges faced by community pharmacy based medication assessment 
programs are consistent across Canada and around the world, which should encourage pharmacy 
organizations to work collectively to improve these types of programs based on the clear and 
consistent areas of concern shown in the research.  
  
7.5 Findings Contradicting the Current Literature 
 This study also reported some results that conflict with previous research on community 
pharmacist-led medication assessments. For example, respondents to the MedsCheck survey in 
Ontario identified some barriers that were not highly ranked in this study, such as: forgetting to 
offer the service and lack of a private room. 28 Data from the UK and Qatar have also identified 
the lack of a private counseling area as a barrier. 37,38 Very few respondents to this SMAP study 
selected “I frequently forget to offer service to patients who are eligible’ (n=11/199, 5.5%) and 
‘lack of a private consultation area in my pharmacy’ (n=11/199, 5.5%) as one of their top three 
barriers. In fact, 33.3% of respondents in this study indicated ‘availability of a private counseling 
area in my pharmacy’ was one of the top three facilitators. An explanation for this discrepancy 
may be the span of time between when the surveys were conducted. The UK and the Ontario 
based surveys were conducted in 2006 and 2007 respectively, and at the time the MedsCheck 
program was the only funded medication assessment program in Canada. 28,37 The survey in Qatar 
was conducted in 2012, prior to any medication assessment programs being implemented in that 
country. 38 This survey of Saskatchewan pharmacists was conducted several years later (in 2016) 
when conducting medication assessments within the community pharmacy setting had become a 
more common practice. It is likely, although not supported by any publications, that in the nine-
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year span, many pharmacies in Saskatchewan and in Canada have either been built or renovated 
to include a private consultation area to facilitate the provision of clinical services.  
 An additional barrier that was reported in the focus groups conducted with pharmacists in 
British Columbia, that was not ranked highly in this study, was pharmacists’ stating that they had 
difficulty determining which patients would benefit from a medication assessment. 13 In this 
study, ‘Determining which patients would benefit from the service’ was the least selected barrier 
(n=4/199, 2%). A possible explanation for this discrepancy is the difference in the eligibility 
criteria in BC and Saskatchewan. Patients were eligible to receive a medication assessment 
through the BC pilot project if they were simply taking at least one medication. 13 Saskatchewan 
residents are eligible for the SMAP if they are 65 years or older, living in their own residence 
and are taking five or more chronic medications, or taking an anticoagulant medication, or taking 
a medication listed in the most current Beers Criteria. 4,5 Consequently, the Saskatchewan 
eligibility criteria may be assisting pharmacists with identifying patients to recruit for the service.  
Saskatchewan pharmacists responding to this study also appear to have demonstrated 
more confidence in their ability to provide medication assessment services than what has been 
previously documented in the literature, despite the fact that no additional training was provided 
to pharmacists in Saskatchewan prior to launching the SMAP. Only 8.5% of respondents in this 
study selected ‘I am not confident in my ability to perform a medication assessment’ as a barrier 
and only 5.5% selected this as one of their top three barriers. As well, when asked for their level 
of agreement with the statement “I am confident in my ability to identify drug related problems 
when I perform SMAP medication assessments”, 88.2% respondents agreed or strongly agreed. 
The majority of respondents, 96.4%, also agreed or strongly agreed that they felt comfortable 
discussing their recommendations with patients and 81.7% agreed or strongly agreed that they 
felt comfortable making recommendations to physicians.  
Data from other studies have found much lower levels of confidence amongst community 
pharmacist respondents. In semi-structured interviews conducted with community pharmacists 
who participated in the General Practitioner-Pharmacist Collaboration study in New Zealand, 
one of the four themes was a feeling that the pharmacists’ clinical knowledge and skills were not 
adequate to provide medication assessments. 39 From the results of a survey of pharmacists in 
Qatar, it was found that only 16.4% of respondents agreed that they had sufficient training to 
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provide MUR services and 95.6% of respondents agreed that a training program to orient and 
educate pharmacists should be provided. 38  
It is difficult to explain why Saskatchewan pharmacists appear to feel more confident in 
their ability to provide medication assessments than what was previously documented in the 
literature. However, there was some inconsistency between the positive responses to the Likert-
scale questions related to confidence and the more negative tone of the responses to the open-
ended questions. Respondents to the open-ended questions made comments regarding feeling 
unprepared to offer medication assessment services and the lack of training and support available 
to help them provide a high quality service. Comments in the open-ended responses were also 
made in regard to pharmacists not having the knowledge and skills to assess and manage 
complex patients.  
The results from the Likert-style/closed-ended questions may have been affected by 
social desirability bias, “the tendency of research subjects to give socially desirable responses 
instead of choosing responses that are reflective of their true feelings”. 63 This means that some 
pharmacists may have answered the questions according to what they felt the socially acceptable 
response should be. The effects of a social desirability bias may help to explain why pharmacists 
appear to be more confident in providing medication assessment services than what had been 
previously documented in the literature. Pharmacists may feel that they should posses the skills 
and knowledge and be confident in their ability to offer medication assessments and therefore 
they may have felt inclined to answer questions in this way. The answers to the closed-ended 
questions may have been more afflicted by this bias, as they were overwhelmingly positive in 
contrast to the responses to the open-ended questions. This highlights the importance of 
collecting different types of data such as the addition of open-ended questions in a questionnaire 
consisting mainly of Likert-style questions. Had this questionnaire only consisted of the Likert-
style and multiple-choice questions it may have appeared that there were very few issues with 
the SMAP as most of the responses were positive. The additional data from the open-ended 
questions, although time consuming to analyze, were very valuable to creating a more accurate 
picture of the SMAP and the struggles faced by some pharmacists.     
 
7.6 New Findings that add to the Existing Literature 
7.6.1 SMAP Eligibility and Access 
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Two of the barriers identified in this study have not been previously reported in the 
literature, both of which were ranked in the top three barriers by the respondents (Figures 33 & 
34). These barriers are: ‘many patients who need the service are not eligible’ and ‘difficulty in 
having patients come to the pharmacy due to their reduced mobility or other medical conditions’. 
It is not completely surprising that these issues were not identified in previous studies, as not all 
medication assessment programs outside of Saskatchewan limit the service to people over the 
age of 65 and not all require the service to be provided in-person. However, patients who have 
their prescription drugs insured by Federal programs (such as NIHB) are not eligible for any of 
the medication assessment programs in Canada, so it is surprising that this finding has not been 
identified previously in the literature, as it would be a problem with all medication assessment 
programs in Canada, including those that have already been investigated. This finding suggests 
that health policy decision makers might consider revising the SMAP accordingly to improve 
access to this service. In an article summarizing the eligibility criteria for medication assessment 
programs in Canada, it was found that the eligibility requirements were highly inconsistent 
across the provincially funded programs and none were based on validated criteria for selecting 
high-risk patients. 3 Perhaps a combined effort across all Canadian provinces to develop a 
common set of eligibility criteria would be useful solution to this issue.  
The requirement for a face to face interview is likely meant to encourage a high quality 
interaction where both the patient and the pharmacist are fully engaged in the interview, however 
pharmacists responding to the survey brought to light that requiring patients to physically come 
to the pharmacy for the interview was a barrier for some patients due to mobility or medical 
conditions. Allowing telephone interviews could make the SMAP more accessible to patients 
who might benefit from the service, but who cannot attend an in-person appointment.  
 
7.6.2 Quality of assessments by some pharmacists 
Another finding from this study that has not been reported in previous research was 
respondents’ concern regarding the quality of the medication assessments of other pharmacists. 
Respondents in this study felt that poor quality assessments performed by other pharmacists 
would not only affect patient care, but also how physicians and patients viewed the program. 
This study did not assess the quality of the services being provided under the SMAP, but this 
 90 
finding suggests that additional investigations be performed to determine if there is indeed a 
quality issue with some pharmacists within the program.   
 
7.6.3 Lack of patient information 
Respondents to this study indicated that they lacked adequate patient information to 
complete their assessments, which has been reported in other research, however, in this survey 
pharmacists were asked additional questions to explore this topic further. There was an 
interesting trend seen in the answers to some of the Likert-style questions. First, 88.2% of 
respondents indicated that they agreed or strongly agreed that they were confident in their ability 
to identify drug related problems when performing SMAP assessments; however in the question 
immediately following, 67.2% of respondents indicated that they agreed or strongly agreed that 
they sometimes have trouble identifying drug related problems because they do not have enough 
information about the patient’s medical history. It seems inconsistent that the majority of 
respondents are confident in their ability to identify drug related problems and the majority of 
respondents also have trouble identifying drug related problems because of a lack of patient 
medical history. Interestingly, even though the majority of respondents identified that a lack of 
patient information hindered their ability to identify drug related problems when providing 
SMAP assessments, the majority of respondents (57.4%) also indicated that they “rarely” or 
“never” contacted the physician to request additional information from the patient’s chart. The 
inconsistency seen in this line of questioning may also be explained by the affects of a social 
desirability bias. As mentioned previously, pharmacists may have felt inclined to agree that they 
were confident in their ability to identify drug related problems when responding to that question 
whether they truly were confident or not because they felt that they should be confident. 
However, when presented with the questions regarding a lack of patient information to identify 
drug related problems and whether or not they contact physicians for additional information, they 
may have been able to objectively identify what actually takes place in their practice and would 
provide responses to these questions that more closely represented reality.   
The inadequate patient information barrier that was noted by respondents of this study 
may at least partially be explained by poor utilization of existing electronic health information 
sources that are available to all Saskatchewan pharmacists. Pharmacists in Saskatchewan have 
access to patient information in the Pharmaceutical Information Program (PIP) and electronic 
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Health Record (eHR) Viewers, which have information related to prescription medications and 
laboratory test results from any pharmacy or lab in the province. Accessing and reviewing the 
information in the PIP is a mandatory requirement to complete a SMAP assessment, however 
only 71.7% of respondents in this study indicated that they “always” access and view 
information from the PIP when completing a SMAP assessment. Similarly, only 85.1% of 
respondents indicated that they have access to the eHR Viewer (all pharmacists can access the 
database, but they must set up an account prior to the first time they use it), and of those with 
access, only 59.6% indicated that they “always” access information from the eHR Viewer when 
completing a SMAP assessment.  
 
7.6.4 Managing complex patients 
Pharmacists in this study also reported that it was challenging to manage complex 
patients under the SMAP, which is a finding that has not been previously reported in the 
literature.  This is not surprising, considering the fact that respondents also found that a lack of 
time was the key overall barrier to providing these services within community pharmacies, and 
managing complex patients would be particularly time consuming. Respondents suggested that 
these complex patients should be managed by pharmacists in a different practice setting (e.g., a 
hospital or clinic), who might have more time and additional expertise. However, respondents 
did not mention any available referral sources for this purpose, nor did any report actually 
referring a complex patient to a pharmacist in a hospital or a clinic. This suggests that there is a 
lack of awareness of pharmacists who work these non-community pharmacy settings in 
Saskatchewan who might be able to accept referrals and manage these complex patients. 
Consequently, it may be helpful to develop and disseminate a referral database for this purpose.  
 
7.6.5 Factors affecting the number of SMAP assessments performed 
The secondary analysis performed in this study also revealed some previously 
unreported, but also unsurprising results. A comparison between whether or not pharmacists 
indicated that they enjoyed performing SMAP assessments and the number of SMAP 
assessments completed found that pharmacists indicating that they enjoy performing SMAP 
assessments are likely to complete more assessments. This stands to reason that pharmacists who 
enjoy doing the assessments would seek out more opportunities to complete them. Similarly, 
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pharmacists who indicated that they feel comfortable making recommendation to physicians 
were also found to be more likely to indicate they complete more SMAP assessments. This also 
seems logical as pharmacists who are uncomfortable making recommendations to physicians 
would be unlikely to seek out opportunities to deliver a service that is intended to discover drug 
related problems and requires the pharmacist to contact the physician with recommendations.  
 
7.7 Limitations of the Study 
 As with all research, this study faced a number of limitations. The response rate of this 
study (20.3%) is a limitation that creates the potential for non-response bias, which is the 
possibility that there are differences between individuals who responded to the survey and those 
who did not.  This may affect the generalizability of the results to the entire population of 
Saskatchewan community pharmacists. 64 The optimal response rate to a survey suggested by 
some medical journals in Canada and the United States can be as high as 60%. 65 Consequently, 
the response rate in this study would appear quite low compared to what is considered optimal. 
However, this is a challenge that has been experienced by many studies that have attempted to 
recruit practicing healthcare professionals. It has been well documented that response rates from 
healthcare professionals are lower than response rates from the general population and that the 
response rates to surveys targeting healthcare professionals are continually declining. 64,66,67 In a 
sample of surveys sent to various healthcare practitioners and published between 2001 and 2007, 
the response rate varied between 13-85% for web-based surveys and 23-81% for postal surveys. 
68 It was reported in 2002 that response rates ranging from 13-39% are typical for surveys 
targeting healthcare workers. 66 More recently, to investigate the response rate of pharmacists 
practicing in the United States, researchers sent out a survey by postal mail, email, or a hybrid 
(postcards with an online link) and varied the length of the questionnaire, the location of the 
demographic questions, and recorded the gender of the respondents. 67 It was found that the 
delivery mode was the only variable that affected the response rate, with the hybrid approach 
having a total response rate of 3.2%; email, 6.8%; and postal mail, 21.0%. 67 The researchers 
suggested that their response rates may have been slightly higher had they offered an incentive, 
as incentives have been shown to improve response rates, however they argued that there is still 
a large gap between the reality of the response rates that are now typically obtained when 
surveying healthcare practitioners and those desired by reviewers and publishers. 67  
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 The response rate in this study may have been improved had the survey been 
administered by postal mail, if an incentive had been offered to all respondents instead of a 
limited number, and if additional reminder contacts had been made with the respondents. 
Unfortunately, we did not have access to practicing pharmacists mailing addresses, nor the funds 
required to mail questionnaires (and reminders) to over 1000 potential respondents. It was also 
not possible to send more than one reminder email, as the Pharmacy Association of 
Saskatchewan (PAS) preferred not to burden its members with multiple emails.  
Although the response rate in this study was not optimal, the analyses that were 
performed to assess for non-response bias (See section 6.10: Non-response Bias), suggest that 
the respondents were representative of typical practicing community pharmacists in 
Saskatchewan.  
 A second limitation of this study is that the organization that distributed the survey on 
behalf of the researchers (PAS) is a voluntary professional organization that does not include 
100% of pharmacists in Saskatchewan. Originally the Saskatchewan College of Pharmacy 
Professionals (SCPP) was approached to distribute the questionnaire, because all pharmacists in 
Saskatchewan must be SCPP members in order to be licensed in the province. However, SCPP 
preferred that the questionnaire be distributed by PAS, as the SMAP is a program was created 
and is overseen by PAS. At the time of questionnaire distribution 82.6% of all pharmacists in 
Saskatchewan were PAS members. 41,46 Consequently, some pharmacists who may have been 
eligible to complete the questionnaire were excluded. This could limit the generalizability of the 
results if pharmacists practicing in community and not having a PAS membership had opinions 
or experiences with the SMAP that differed from pharmacists with PAS memberships. However, 
since this potential limitation represents a relatively small proportion of practicing pharmacists, it 
is unlikely that it would have impacted the overall findings and conclusions of the research in a 
meaningful way.  
 A further limitation is the possibility that pharmacists not practicing in community 
pharmacy could have completed the questionnaire. Pharmacists are able to voluntarily self-
declare their primary practice site (e.g. community, hospital, industry, etc.) when they apply for a 
PAS membership, however it was decided to not use this information to distribute the 
questionnaire to only those pharmacists identifying their primary practice site as ‘community 
pharmacy’ because there was a greater risk of excluding pharmacists who chose not to declare a 
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primary practice site, who practiced in community pharmacy on a part-time or casual basis (but 
who declared another site as their primary site), or who had changed practice sites but had not 
updated this information with PAS. Consequently, the invitation was sent to all PAS members 
and only those who worked in community pharmacy were asked to respond. This created the risk 
that pharmacists not currently practicing in the community pharmacy setting could choose to 
respond to the survey. Responses from pharmacists not practicing in the community pharmacy 
setting could affect the results, however it was decided that the risk of this was small compared 
to the risk of excluding pharmacists from answering the survey by only distributing to those who 
had declared community pharmacy as their primary practice site. To further minimize the risk of 
collecting data from pharmacists without experience with the program, respondents were asked 
about their level of involvement with the SMAP. Only 20 (8.8%) respondents indicated that they 
had never completed an SMAP and these pharmacists were excluded from responding to further 
questions regarding their experiences with providing SMAP services.  
 The potential for researcher bias is also a consideration for this study. Since the primary 
investigator is also a practicing community pharmacist who has personal experience with the 
SMAP, pre-conceived notions about the SMAP had the potential to affect the line of questioning 
that was developed in the questionnaire and the interpretation of the free-text responses. To 
reduce the potential impact of researcher bias, the questionnaire was developed with input from 
several faculty members at the College of Pharmacy and Nutrition and was reviewed by several 
key stakeholders. As well, three different individuals analyzed the free-text responses following 
the content analysis guidelines (Appendix D) and final themes were developed through 
discussion between the three individuals. An external (non-pharmacist) auditor then reviewed the 
free-text responses and the final themes to confirm that the themes aligned well with the original 
responses.  
 Another potential area for bias was that the three individuals who analyzed the free-text 
responses were the primary investigator, her supervisor, and another graduate student overseen 
by the same supervisor. As these individuals were working together on projects and were all 
involved in the pharmacy profession, they may have shared similar opinions and biases that 
could affect how they analyzed the responses. This may have been minimized by the fact that the 
three individuals came from different backgrounds and experiences in the pharmacy profession. 
As mentioned earlier, Dr. Derek Jorgenson, is a faculty member at the University of 
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Saskatchewan with experience in clinical pharmacy and research; Katherine Lysak, is a former 
graduate student with experience working in hospital pharmacy; and Krysta Currie, the primary 
investigator, had experience working in community pharmacy. As well, to detect if the analysis 
was biased, another graduate student who was not involved in the pharmacy profession and who 
did not have the same supervisor acted as an external auditor. The external auditor confirmed 
that the themes developed did align with the original responses provided by the respondents, 
strengthening the trustworthiness and credibility of the analysis and resulting themes.  
 Since the invitation to participate in the survey was distributed by PAS, the association 
responsible for creating an overseeing the SMAP, respondents may have also felt wary of 
selecting negative responses. Had the survey been distributed by a different party or directly 
from the researchers themselves, respondents may have felt more comfortable selecting negative 
responses. This potential issue was hopefully mitigated by the guarantee of anonymity and the 
fact that no identifying information was requested from respondents in the SMAP survey. 
Although the responses to the majority of the Likert-style questions were overwhelmingly 
positive, the responses to the open-ended questions were more negative, suggesting that there 
was at least some level of respondent comfort in sharing negative viewpoints.  
 All responses to the survey where included in the analysis regardless of how many 
questions the respondent answered. In some research a minimum number of items must be 
answered for the data from that respondent to be included in the final analysis or adjustments are 
made to account for the missing information. For this research project there was no minimum 
number of answers required for the respondents data to be included in the analysis and no 
attempt was made to make adjustments to account for missing information. The resultant missing 
data could potentially affect the reliability of the data for individual questions. To be transparent 
about missing responses, the number of respondents was included for each question.  
 Finally, respondents’ limited exposure to the SMAP may be an additional limitation to 
the findings. The majority of respondents (79.2%) indicated that they complete between one and 
five SMAP assessments in a typical month and 10.6% indicated that the do not complete any 
SMAP assessments in a typical month. Given this information, it appears that the respondents to 
the survey did not have a great deal of experience in providing the SMAP service, which may 
limit the generalizability of the results. The majority of the respondents were basing their 
perceptions and experiences on a limited amount of actual experience in providing the services. 
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However, there were 30,173 SMAP medication assessment billed to the Ministry of Health from 
June 2013 to June 2016, which averages to approximately 838 SMAP assessments completed per 
month, provided by over 1000 pharmacists. 41 Therefore, the number of monthly SMAP 
assessments performed by the respondents of this study is representative of the typical 
pharmacist’s SMAP workload in Saskatchewan.  
 
7.8 Suggestions for Future Research 
This project was intended to explore pharmacists’ attitudes towards and experiences with 
the SMAP, and several areas of further research still exist.  
The SMAP has not been evaluated to determine if the program is actually fulfilling its 
intended purposes; however, research on other similar medication assessment programs suggests 
that it is possible for these types of services to achieve at least some of these goals (e.g., 
resolution of drug related problems, improved prescribing, reduction in adverse drug reactions, 
improved quality of life, reduced drug costs). 6-15 Nevertheless, future research should focus on 
confirming the perceptions of the pharmacists in this study by determining if the SMAP is 
actually fulfilling its intended purposes. As well, research to investigate the SMAPs potential to 
reduce hospitalizations and mortality would be worthwhile pursuing. 
Research building on the results of this study could also be done to attempt to rank the 
barriers and facilitators to determine which are more important to Saskatchewan pharmacists. As 
well, follow-up focus groups could be done to obtain additional data on pharmacists perceptions 
and experiences with the program. A focused study on pharmacies and pharmacists who are high 
users of the SMAP to identify how they have been able to overcome barriers and what 
facilitators are helping them to complete more SMAP assessments than the majority of 
pharmacies, would also be valuable.  
In the responses to the free-text questions, respondents expressed concerns over SMAP 
quotas and poor quality assessments performed by their colleagues. Future research to 
investigate how many pharmacies in Saskatchewan impose quotas for clinical services such as 
the SMAP and if these quotas impact the quality and benefit received is needed. In addition, this 
study did not assess the quality of the services being provided under the SMAP, but the findings 
suggest that additional investigations need to be performed to determine if there is a quality 
issue.   
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Respondents to the survey also seemed to have higher confidence in their ability to 
perform medication assessments and identify drug related problems than what had been 
documented in previous research. As such, further research focused on Saskatchewan 
pharmacists’ confidence and actual performance in conducting SMAP medication assessments 
would be valuable. Interestingly, it was found that the respondents recognized that they were 
lacking patient information to complete assessments and identify drug related problems, but also 
did not make efforts to seek out this information. Research to identify the reasons why 
pharmacists do not seek out additional information from physicians, that they have 
acknowledged they are lacking, would be useful to identify and resolve the issues so that 
pharmacist can have access to the information needed to effectively identify and attempt to 
resolve drug related problems.  
 
7.9 Suggestions for Improvements to the SMAP 
 Based on the findings of this research project as a whole, some areas for improvement to 
the SMAP emerged. As stated previously in Section 7.3, respondents suggested several areas for 
improvements that would help them to fulfill the purposes of the SMAP. Some of the 
improvements suggested by the respondents will likely require substantive changes to the 
program, community pharmacy practice, and the attitudes and practices of prescribers; however 
some less complex improvements (that could be possibly be implemented in the near future) 
were also identified.  
Many respondents identified the SMAP documentation forms as an area of frustration. 
Specifically, the need to duplicate information in several places was mentioned by many 
respondents. To amend this, the forms could be revised to eliminate the need to duplicate 
information. Some pharmacists also mentioned that the SMAP documentation forms were 
integrated into their pharmacy dispensing software, making documentation quicker and 
retrieving the information at a later date more convenient; however, not all dispensing software 
currently offers this option. As an alternative to integrating the forms into dispensing software, 
some respondents suggested that the SMAP documentation forms should be accessible through 
each patients PIP profile so that all healthcare providers have access to the information on an as 
needed basis and it could easily be updated from year to year. Integrating the SMAP 
documentation forms into an online resource accessible to all healthcare providers in 
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Saskatchewan, such as the PIP or eHR Viewer, could ease the burden of documentation and 
make the information accessible for future use by healthcare providers in the patient’s circle of 
care.  
 Many respondents seemed to believe that physicians are either not aware of the SMAP or 
had negative thoughts towards it. It is difficult to determine if this is accurate without surveying 
physicians about the SMAP; however, these perceptions by pharmacists, whether justified or not, 
may be hindering communication between physicians and pharmacists. If pharmacists are not 
comfortable contacting physicians for additional information to complete a comprehensive 
assessment or to make suggestions to optimize a patient’s drug therapy, then the mediation 
assessments may offer little benefit to patients. To rectify the communication gap, one 
respondent suggested sending a pre-SMAP notification to the patient’s physician before 
conducting a SMAP to let the physician know that one will be completed and to offer the 
physician an opportunity to suggest anything that should be reviewed during the assessment. 
This pre-notification may strengthen awareness of the program and would give physicians an 
opportunity to contribute to the discussion, which would perhaps encourage them to see value in 
the program. Some other respondents also suggested that patients be asked to make an 
appointment with their physician to discuss changes suggested by the pharmacist as a result of a 
SMAP medication assessment. This would allow physicians an opportunity to have a discussion 
with their patients and would ensure that physicians are compensated for their time reviewing the 
suggestions and making the appropriate changes. Several respondents also suggested using a 
personalized physician communication form, as they felt the one provided by PAS was not 
reader-friendly and that they received more responses from physicians when using their own 
form. Making a pre-SMAP communication with a prescriber a common practice, using 
personalized forms for communication with prescribers, and suggesting that patients requiring 
major drug therapy changes book an appointment to see their physician could all be strategies to 
improve communication about SMAP medication assessments. 
 Several respondents felt that patients who would benefit from a medication assessment 
were prevented from participating in the service due to the requirement for a face-to-face 
interview. Many felt that telephone interviews should be permitted in circumstances in which the 
patient in unable to come to the pharmacy for the interview. Some respondents also suggested 
that another option would be to fund in-home medication assessments, meaning that pharmacies 
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would be paid an additional fee when they were required to visit a patient in their home to 
complete the SMAP.  
 Lastly, many respondents felt that they could not adequately assess complex patients in 
the community pharmacy setting. They suggested that complex patients be referred to 
pharmacists (in other settings) with more expertise and time, however, based on the responses it 
was clear that pharmacists were not aware of the referral options (to other pharmacists in other 
settings) that already exist. It would be beneficial to include a list of referral options along with 
the other SMAP documentation forms so that community pharmacists are made aware of the 
referral options and the contact information is readily accessible.  
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CHAPTER 8 
CONCLUSIONS 
 
 This study revealed that pharmacists in Saskatchewan perceive that the Saskatchewan 
Medication Assessment Program (SMAP) is fulfilling its intended purposes, however 
examination of some participant responses raises suspicion that underlying issues with the 
program and its current implementation may be interfering with the fulfillment of its intended 
purposes. The findings revealed that community pharmacists experience several barriers to 
providing SMAP assessments, the most notable being a lack of time. In their responses, 
pharmacist also provided several suggestions for overcoming the barriers that they had 
identified. Ultimately it appears that Saskatchewan pharmacists see potential for the SMAP, but 
also deal with several barriers to providing the service that need to be addressed.  
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APPENDICES 	
APPENDIX A: INVITATION 
From: Pharmacy Association of Saskatchewan (PAS) 
To: (PAS member) 
Sent: (Date) 
Subject: SMAP Pharmacist Experience Survey Invitation 
 
Dear Saskatchewan Pharmacist, 
 
We are seeking help from Saskatchewan pharmacists practicing in community pharmacies to 
improve the Saskatchewan Medication Assessment Program (SMAP). We are looking to capture 
pharmacists’ experiences with and perceptions of the SMAP. The questionnaire focuses on 
whether or not pharmacists believe the SMAP is meeting its intended objectives and identifying 
opportunities to improve the program. You responses will be extremely valuable in strengthening 
SMAP for the future. 
 
Please fill out this questionnaire only if you currently practice in the community pharmacy 
setting on a full, part-time or casual basis.   
 
The questionnaire should take about 15 minutes to complete and is compatible on a desktop 
computer or mobile device.  To show our appreciation for your participation, the first 50 
respondents can receive a $10 Tim Hortons e-gift card and all respondents will be entered into a 
draw to win one of eight $250 Visa gift cards. Pharmacists who complete the questionnaire will 
also have access to the findings soon after completion of the study. To begin the questionnaire, 
click on the link below: 
 
https://fluidsurveys.usask.ca/s/SMAP/ 
 
This questionnaire is anonymous.  Responses will be kept secure and cannot be linked to the 
respondent.  In the interest of protecting participants’ confidentiality, the identifying information 
gathered for the purposes of providing participants with incentives cannot be associated with the 
questionnaire responses.  Although the data from this research project may be included in a 
master’s thesis, published and presented at conferences, the data will be reported in aggregate 
form, so that it will not be possible to identify individuals.  
 
Participation is voluntary and individual questions can be left blank if desired.  Completing the 
online questionnaire implies consent for your participation in the study and for the researchers to 
use the data for the purposes of conducting the study.  
 
The Pharmacy Association of Saskatchewan (PAS) has provided funding to make this research 
possible. 
 
This survey is hosted by Fluid Survey, a USA owned company, see the following for more 
information on Fluid Survey Data Privacy in Canada. 
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This research project has been approved on ethical grounds by the University of Saskatchewan 
Behavioural Research Ethics Board.  Any questions regarding your rights as a participant may be 
addressed to that committee through the Research Ethics Office ethics.office@usask.ca (306) 
966-2975. Out of town participants may call toll free (888) 966-2975. 
 
By completing and submitting the questionnaire, YOUR FREE AND INFORMED 
CONSENT IS IMPLIED and indicates that you understand the above conditions of 
participation in this study. 
 
Should you have and questions or concerns, please contact Derek Jorgenson at 
derek.jorgenson@usask.ca. 
 
Thank you for considering this request, 
 
Dr. Derek Jorgenson 
Associate Professor of Pharmacy 
Director, Medication Assessment Centre 
College of Pharmacy and Nutrition 
University of Saskatchewan 
Health Sciences Bldg, E-wing, Rm 3206 
104 Clinic Place  
Saskatoon, Sask  S7N 2Z4 
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APPENDIX B: REMINDER 
 
From: Pharmacy Association of Saskatchewan (PAS) 
To: (PAS member) 
Sent: (Date) 
Subject: Reminder: SMAP Pharmacist Experience Survey Invitation  
 
Dear Saskatchewan Pharmacist, 
 
A couple weeks ago you received a request to complete a questionnaire regarding your 
experiences with the Saskatchewan Medication Assessment Program (SMAP). If you have 
already completed the questionnaire, thank you for you time.  If you have not, we would be very 
pleased if you took a few moments now to complete the questionnaire before it closes and your 
opportunity to provide feedback to improve the SMAP will be lost. 
 
Please fill out this questionnaire only if you currently practice in the community pharmacy 
setting on a full, part-time or casual basis.   
 
The questionnaire should take about 15 minutes to complete and is compatible on a desktop 
computer or mobile device. To show our appreciation for your participation, the first 50 
respondents can receive a $10 Tim Hortons e-gift card and all respondents will be entered into a 
draw to win one of eight $250 Visa gift cards.  Pharmacists who complete the questionnaire will 
also have access to the findings soon after completion of the study. To begin the questionnaire, 
click on the link below: 
 
https://fluidsurveys.usask.ca/s/SMAP/ 
 
This questionnaire is anonymous.  Responses will be kept secure and cannot be linked to the 
respondent.  In the interest of protecting participants’ confidentiality, the identifying information 
gathered for the purposes of providing participants with incentives cannot be associated with the 
questionnaire responses.  Although the data from this research project may be included in a 
master’s thesis, published and presented at conferences, the data will be reported in aggregate 
form, so that it will not be possible to identify individuals.  
 
Participation is voluntary and individual questions can be left blank if desired.  Completing the 
online questionnaire implies consent for your participation in the study and for the researchers to 
use the data for the purposes of conducting the study.  
 
The Pharmacy Association of Saskatchewan (PAS) has provided funding to make this research 
possible. 
 
This survey is hosted by Fluid Survey, a USA owned company, see the following for more 
information on Fluid Survey Data Privacy in Canada. 
 
This research project has been approved on ethical grounds by the University of Saskatchewan 
Behavioural Research Ethics Board.  
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addressed to that committee through the Research Ethics Office ethics.office@usask.ca (306) 
966-2975. Out of town participants may call toll free (888) 966-2975. 
 
By completing and submitting the questionnaire, YOUR FREE AND INFORMED 
CONSENT IS IMPLIED and indicates that you understand the above conditions of 
participation in this study. 
 
Should you have and questions or concerns, please contact Derek Jorgenson at 
derek.jorgenson@usask.ca. 
 
Your time is very much appreciated. 
 
Thank you, 
 
Dr. Derek Jorgenson 
Associate Professor of Pharmacy 
Director, Medication Assessment Centre 
College of Pharmacy and Nutrition 
University of Saskatchewan 
Health Sciences Bldg, E-wing, Rm 3206 
104 Clinic Place  
Saskatoon, Sask S7N 2Z4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
APPENDIX C: QUESTIONNAIRE 
 
1. Please indicate your level of involvement with the Saskatchewan Medication Assessment 
Program (SMAP). 
 
! I have never heard of the SMAP. (Skip Part B and go directly to Part C: Demographics) 
! I am aware of the SMAP, but I have never completed a medication assessment through this 
program. (Skip questions relating to a pharmacists personal experience with performing a SMAP 
medication assessment: 2; Section 1: 5, 6, 7 8, 9, 10, 12, 13, 14, 15, 24, 25; Section 2: 3; Section 
3: 1, 3(yes)) 
! I have completed at least one medication assessment through the SMAP. 
 
2. Indicate the number of SMAP medication assessments you personally complete in a typical 
month. 
! 0 
! 1-5 
! 6-10 
! 11-20 
! 21 + 
 
3. How many SMAP assessments are completed at your pharmacy (by all pharmacists including 
yourself) in a typical month? If you work in multiple community pharmacies, select the answer 
for the pharmacy you work in most often. 
! 0 
! 1-5 
! 6-10 
! 11-20 
! 21+ 
!not sure 
 
Part A  
When the Saskatchewan Medication Assessment Program (SMAP) was created, the Drug Plan 
and Extended Benefits Branch of the Saskatchewan Ministry of Health released a document that 
outlined the policies and procedures for Saskatchewan pharmacists. This document can be 
accessed at the Pharmacy Association of Saskatchewan (PAS) website under Professional 
Services “Saskatchewan Medication Assessment Program (SMAP) Policy Sept 2015”. A section 
of this document lists seven purposes of the SMAP, which are: 
- To provide safe and effective medication therapy to seniors living in the community; 
- To improve patient safety and patient outcomes; 
- To prevent drug related problems, emergency room visits or hospitalizations; 
- To reduce duplication and/or wastage of medication; 
- To optimize medication adherence; 
- To provide support to seniors living in the community that will allow them to age within 
their own home; 
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- To assist the patient and/or caregiver with appropriate and cost-effective medication 
administration 
Saskatchewan residents who are 65 years or older and living in their own residence, a 
personal care home, approved private service home or a group home are eligible for SMAP 
medication assessments if they are: 
• Taking 5 or more chronic medications (prescription and non-prescription) OR 
• Taking and anticoagulant OR 
• Taking a medication on the Beers List AND 
• Give expressed written consent to receive the service 
Please refer to the “Saskatchewan Medication Assessment Program (SMAP) Policy Sept 2015” 
link above if you wish to have more detailed information on patient eligibility. 
The questions in Section 1 of this questionnaire focus on determining your perceptions of 
whether or not the SMAP is achieving the seven stated purposes. 
Considering the way the SMAP is currently utilized in your pharmacy please answer the 
questions in Section 1 and 2. 
Section 1: 
 
1. Assessments provided through the SMAP improve medication safety for seniors.  
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
2. Assessments provided through the SMAP ensure that seniors are taking the most effective 
medication therapy. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
3. Seniors who receive a SMAP assessment are more likely to have improved health outcomes 
compared with seniors who do not receive an assessment. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
4. Assessments provided through the SMAP prevent drug-related problems for seniors.  
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
5. I am confident in my ability to identify drug-related problems when I perform SMAP 
medication assessments. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
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6. Sometimes I have trouble identifying drug-related problems when completing a SMAP 
assessment because I do not have enough information about the patient’s medical history.  
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
7. When you are completing a SMAP assessment, how often do you contact the physician to 
request additional information from the patient’s chart? 
Always Almost Always Sometimes Rarely Never 
 
8. When completing a SMAP assessment I feel comfortable discussing my recommendations 
with patients.  
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
9. If you answered “disagree” or “strongly disagree” for the previous question, please explain 
why you are not comfortable making recommendations to patients. 
 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
____________________________________________________________ 
 
10. How often do patients agree with the recommendations that you make when completing a 
SMAP assessment.  
Always Almost 
always 
Sometimes Rarely Never I don’t know 
 
11. The SMAP encourages collaboration between pharmacists and physicians.  
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
12. When completing a SMAP assessment I feel comfortable making recommendations to 
physicians. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
13. If you answered “disagree” or “strongly disagree” for the previous question, please explain 
why you are not comfortable making recommendations to physicians. 
 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
____________________________________________________________ 
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14. When completing a SMAP assessment, how often are your recommendations accepted by the 
physician? 
Always Almost 
always 
Sometimes Rarely Never I don’t know 
 
15. How do you typically communicate with physicians regarding SMAP assessments? (select 
all that apply) 
  Fax 
  Phone 
  In-person 
  Other: ___________________ 
 
16. What changes (if any) would you make to the SMAP to make communication with 
physicians more effective? 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
17. An assessment completed through the SMAP is likely to decrease the incidence of 
emergency room visits for seniors. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
18. An assessment completed through the SMAP is likely to decrease the incidence of 
hospitalizations for seniors. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
19. SMAP assessments reduce duplication of medication therapy for seniors. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
20. Providing SMAP assessments to seniors reduces medication wastage. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
21. Seniors who receive an assessment through the SMAP have improved medication adherence 
following the assessment. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
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22. SMAP assessments provide support to seniors living in the community that will allow them 
to age within their own home. 
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
23. SMAP assessments provide an opportunity for pharmacists to assist their patients and/or 
caregivers in administering their medications appropriately  
Strongly Agree Agree Not sure Disagree Strongly 
Disagree 
 
24. During a SMAP assessment, how often do you have patients who use devices (e.g., inhalers, 
eye drops, etc.) demonstrate their technique? 
Always Almost Always Sometimes Rarely Never 
 
25. During a SMAP assessment, how often do you personally assess whether patients are on the 
most cost-effective medications? 
Always Almost Always Sometimes Rarely Never 
 
Section 2: 
 
1. Do you think providing medication assessments through the SMAP is a valuable use of 
pharmacist’s skills?  
! Yes 
! No 
! Not sure 
 
2. If you answered NO, please explain: 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
3.  I enjoy performing SMAP assessments. 
Strongly Agree Agree Neutral Disagree Strongly 
Disagree 
 
4. Do you think the pharmacy profession in Saskatchewan should focus more on services other 
than the SMAP? 
! Yes 
! No 
! Not sure 
 
5. If you answered YES, what other services should pharmacists be focusing on? 
_____________________________________________________________________________
_____________________________________________________________________________
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_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
 
Section 3: 
 
1. How often do you access and view information from the PIP Viewer when completing a 
SMAP assessment? 
Always Almost Always Sometimes Rarely Never 
 
2. Do you have access to the eHR Viewer in your pharmacy? The eHR Viewer provides health 
care providers in Saskatchewan with access to patient information such as laboratory results, 
immunization records, and clinical encounters.  
! Yes (Skip 3 “no”) 
! No (Skip 3 “yes”) 
! Not sure (Skip 3 “no” and “yes”) 
 
If respondent answers “yes”  
3. How often do you use information from the eHR Viewer when completing an SMAP 
assessment? 
Always Almost Always Sometimes Rarely Never 
 
If respondent answers “no” 
3. Why do you not have access to the eHR Viewer? 
! I have never heard of the eHR Viewer 
! The pharmacy I work in has not signed up for access 
! The pharmacy I work in has signed up for access, but I have not  
! Other: (please specify) ____________________________________ 
 
Part B: 
This section (questions 1-5) deals with the barriers and facilitators to fulfilling the official SMAP 
purposes. Please keep the official purposes of SMAP in mind (below) when answering questions 
1-5: 
- To provide safe and effective medication therapy to seniors living in the community; 
- To improve patient safety and patient outcomes; 
- to prevent drug related problems, emergency room visits or hospitalizations; 
- To reduce duplication and/or wastage of medication; 
- To optimize medication adherence; 
- To provide support to seniors living in the community that will allow them to age within 
their own home; 
- To assist the patient and/or caregiver with appropriate and cost-effective medication 
administration 
 
 119 
1. From the list provided below, please indicate all of the barriers that make it difficult for you 
personally to provide SMAP medication assessments. Select all that apply. 
o Inadequate access to patient’s medical records 
o Lack of cooperation with physicians 
o Inadequate remuneration from the Ministry for the program 
o I suspect the service is not helping those that need it the most 
o Poor patient awareness of the program 
o Patient concerns about privacy 
o Lack of patient interest in participating in the program 
o Difficulty in having patients come to the pharmacy due to their reduced mobility 
or other medical problems 
o Lack of a private consultation area in my pharmacy  
o Lack of time 
o Inadequate pharmacist staffing in my pharmacy 
o Interruptions during patient interviews  
o I frequently forget to offer service to patients who are eligible 
o Many patients who need the service are not eligible (e.g., age<65, NIHB) 
o Extensive documentation requirements 
o Unhelpful/complicated Ministry documentation templates and forms   
o Determining which patients would benefit from the service 
o Determining which patients are eligible for the service 
o Inadequate technician/assistant staffing in my pharmacy 
o Lack of support from my employer/manager 
o I am not confident in my ability to perform a medication assessment 
 
2. From the list provided below, please indicate the top three (3) barriers that make it difficult 
for you personally to provide SMAP medication assessments. 
o Inadequate access to patient’s medical records 
o Lack of cooperation with physicians 
o Inadequate remuneration from the Ministry for the program 
o I suspect the service is not helping patients that need it the most 
o Poor patient awareness of the program 
o Patient concerns about privacy 
o Lack of patient interest in participating in the program 
o Difficulty in having patients come to the pharmacy due to their reduced mobility 
or other medical problems 
o Lack of a private consultation area in my pharmacy 
o Lack of time 
o Inadequate pharmacist staffing in my pharmacy 
o Interruptions during patient interviews  
o I frequently forget to offer service to patients who are eligible 
o Many patients who need the service are not eligible (e.g., age<65, NIHB) 
o Extensive documentation requirements  
o Unhelpful / complicated Ministry documentation templates and forms   
o Determining which patients would benefit from the service 
o Determining which patients are eligible for the service 
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o In adequate technician/assistant staffing in my pharmacy 
o Lack of support from my employer/manager 
o I am not confident in my ability to perform a medication assessment 
 
3. Please share any barriers to providing SMAP assessments that you have encountered in your 
practice that are not included in the previous list. 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
4. From the list provided below, please indicate the top three (3) facilitators currently helping 
you to provide medication assessments that fulfill the stated purposes of the SMAP. 
o Good teamwork within my pharmacy 
o Support from my employer/manager 
o Adequate pharmacist staffing in my pharmacy 
o My personal interest/passion in providing medication assessments 
o My personal belief that medication assessments are important to improve the care 
of my patients 
o Strong communication with physicians  
o Strong communication with patients  
o Offering reviews on “appointment only” basis 
o Strong physician support of the program 
o Strong patient awareness of the program 
o Standardized forms and documentation templates from the Ministry 
o Effectively utilizing technician’s role to support me in providing medication 
assessments 
o Availability of a private counselling area in my pharmacy 
o Having adequate skills and knowledge to provide medication assessments 
 
5. Please share any facilitators to providing SMAP assessments that you have identified in your 
practice that are not included in the previous list. 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
6. Please use the space below to comment on any additional suggestions to improve the SMAP. 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
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Part C)  
 
1. What best describes your position? 
 ! Pharmacy owner 
! Pharmacy manager 
! Staff pharmacist 
! Relief/casual pharmacist 
 
2. How many hours do you work in a community pharmacy setting in a typical week? 
 ! Less than 10 hours 
 ! 10 – 20 hours 
 ! 21 – 30 hours 
 ! 31 – 40 hours 
 ! more than 40 hours 
 
3. Please indicate your gender: 
 ! Male 
! Female 
! Prefer not to answer 
 
4. How many years have you been a licensed pharmacist? 
Enter actual number 
  
 
5. What is the population of the community where your pharmacy is located? If you work in 
multiple community pharmacies, select the answer for the pharmacy you work in most often. 
 ! Rural (<5,000) 
 ! Small city (5,000 – 100,000) 
! Large city (Saskatoon or Regina) 
 
6. How would you classify the pharmacy you work in? If you work in multiple community 
pharmacies, select the answer for the pharmacy you work in most often. 
 ! Independent/Banner  
! Franchise 
 ! Chain/Supermarket/Mass merchandiser 
 
7. Are you a(n): 
 ! International pharmacy graduate 
 ! Canadian pharmacy graduate 
 
8. How many prescriptions are filled at your pharmacy in a typical day? If you work in multiple 
community pharmacies, select the answer for the pharmacy you work in most often. 
! < 100 
 ! 101-200 
 ! 201-300 
 ! >300 
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9. Please indicate any/all additional training/education that you have completed (select all that 
apply): 
  Residency (ACPR) 
  ADAPT Certificate in Patient Care Skills (CPhA) 
  CPhA Medication Review Services Program 
  Certified Diabetes Educator (CDE) 
  Certified Respiratory Educator (CRE) 
  Certified Geriatric Pharmacist 
  Advanced Method Certification (Immunization and Injection Training) 
  Board Certification in United States (BPS) 
  Post baccalaureate PharmD 
  Masters Degree 
  PhD Degree 
  Other: (please specify) _______________ 
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APPENDIX D: CONTENT ANALYSIS GUIDELINES 
 
1. Read through the responses once over without highlighting or noting categories. 
2. Read through responses a second time and highlight substantive statements (the 
statements that make a key point). 
3. Note categories that form in your mind as you highlight substantive statements, but do 
not record them at this time. 
4. Take a break from the material. 
5. Go through the responses a third time, mainly the highlighted portions, and make a list of 
categories that the highlighted statements fit into. 
6. Look at the list of categories and determine if some need to be combined or split up. Edit 
the category headings as appropriate. 
7. Go through the responses a fourth time with the list of categories. Check off each 
highlighted statement that fits into one of the categories and put a ? beside each 
highlighted statement that does not fit into one of the categories. Revise or add new 
categories as necessary so that the highlighted statement with ? can now fit into a 
category. You should now have a final list of categories. 
8. Go through the responses a fifth and final time and mark each highlighted statement (by 
colour coding or numbers) to indicate which category it belongs to. Mark key statements 
for use in the final written report. (The book suggests making a grid (or two – one for 
positive statements and one for negative) that has the categories across the top and the 
respondent codes down the side and to make a mark in the corresponding grid when a 
respondent made a statement that fit into the category. It also suggested to type out key 
statements in the corresponding grid so that they could be used in the final report.) 
 
Adapted from: Gillham B. Developing a questionnaire. 2nd ed. London: Continuum; 2007. 
 
